<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Rev Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Nat. Rev. Immunol</journal-id><journal-title-group><journal-title>Nature Reviews. Immunology</journal-title></journal-title-group><issn pub-type="ppub">1474-1733</issn><issn pub-type="epub">1474-1741</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7472682</article-id><article-id pub-id-type="publisher-id">434</article-id><article-id pub-id-type="doi">10.1038/s41577-020-00434-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Immunological considerations for COVID-19 vaccine strategies</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jeyanathan</surname><given-names>Mangalakumari</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Afkhami</surname><given-names>Sam</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Smaill</surname><given-names>Fiona</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Matthew S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4514-1037</contrib-id><name><surname>Lichty</surname><given-names>Brian D.</given-names></name><address><email>blichty@mac.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7856-0663</contrib-id><name><surname>Xing</surname><given-names>Zhou</given-names></name><address><email>xingz@mcmaster.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution>McMaster Immunology Research Centre, </institution><institution>McMaster University, </institution></institution-wrap>Hamilton, ON Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution>Department of Pathology and Molecular Medicine, </institution><institution>McMaster University, </institution></institution-wrap>Hamilton, ON Canada </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution>Michael G. DeGroote Institute for Infectious Disease Research, </institution><institution>McMaster University, </institution></institution-wrap>Hamilton, ON Canada </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.25073.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8227</institution-id><institution>Department of Biochemistry and Biomedical Sciences, </institution><institution>McMaster University, </institution></institution-wrap>Hamilton, ON Canada </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>9</month><year>2020</year></pub-date><fpage>1</fpage><lpage>18</lpage><history><date date-type="accepted"><day>13</day><month>8</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer Nature Limited 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">This Review outlines the guiding immunological principles for the design of coronavirus disease 2019 (COVID-19) vaccine strategies and analyses the current COVID-19 vaccine landscape and the challenges ahead.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Viral infection</kwd><kwd>Vaccines</kwd><kwd>SARS-CoV-2</kwd></kwd-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">The coronavirus disease 2019 (COVID-19) outbreak was first reported in Wuhan, China, in late 2019 and, at the time of writing this article, has since spread to 216 countries and territories<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. It has brought the world to a standstill. The respiratory viral pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 20.1 million individuals and killed more than 737,000 people globally, and counting<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Although physical-distancing and other transmission-mitigation strategies implemented in most countries during the current pandemic have prevented most citizens from being infected, these strategies will paradoxically leave them without immunity to SARS-CoV-2 and thus susceptible to additional waves of infection. Health-care workers, seniors and those with underlying health conditions are at particularly high risk<sup><xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref></sup>. It is widely accepted that the world will not return to its prepandemic normalcy until safe and effective vaccines become available and a global vaccination programme is successfully implemented<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par4">As COVID-19 is new to humankind and the nature of protective immune responses is poorly understood, it is unclear which vaccine strategies will be most successful. Therefore, it is imperative to develop various vaccine platforms and strategies in parallel. Indeed, since the outbreak began, researchers around the world have been racing to develop COVID-19 vaccines, with at least 166 vaccine candidates currently in preclinical and clinical development<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). To meet the urgent need for a vaccine, a new pandemic vaccine development paradigm has been proposed that compresses the development timeline from 10&#x02013;15 years to 1&#x02013;2 years<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. However, there remains a lack of clarity as to what may constitute a safe and immunologically effective COVID-19 vaccine strategy, how to define successful end points in vaccine efficacy testing and what to expect from the global vaccine effort over the next few years. This Review outlines the guiding immunological principles for the design of COVID-19 vaccine strategies and analyses the current COVID-19 vaccine landscape and the challenges ahead.<fig id="Fig1"><label>Fig. 1</label><caption><title>The global COVID-19 vaccine landscape.</title><p>The six major types of candidate vaccine for coronavirus disease 2019 (COVID-19) are illustrated (live attenuated virus, recombinant viral vectored, inactivated virus, protein subunit, virus-like particles and nucleic acid based), showing the number of candidate vaccines that are currently under clinical and preclinical development. The nucleic acid-based platform includes both mRNA vaccines (6 clinical and 16 preclinical) and plasmid DNA vaccines (4 clinical and 11 preclinical). Data obtained from ref.<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p></caption><graphic xlink:href="41577_2020_434_Fig1_HTML" id="d30e275"/></fig></p></sec><sec id="Sec2"><title>Natural and vaccine-induced immunity</title><p id="Par5">Although much remains to be understood regarding the immune response to SARS-CoV-2, and vaccine-induced protective immunity may differ from natural immunity owing to the immune-evasion strategies of the virus, improved understanding of the natural immune response will be instrumental in developing effective vaccine and therapeutic strategies. It is particularly relevant to understand the difference in immune responses between asymptomatic, mild and severe cases and at early and late stages of infection, and to understand why seniors are particularly susceptible to COVID-19, whereas the young are better protected. It is estimated that 40&#x02013;75% of infections may be mild or asymptomatic<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup> and asymptomatic individuals may have a significantly longer duration of viral shedding than their symptomatic counterparts<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Furthermore, that asymptomatic and mildly ill individuals seem to develop low levels of antibody-mediated immunity has important implications for understanding herd immunity.</p><p id="Par6">The initial site of infection of SARS-CoV-2 is the respiratory tract<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. On entry, SARS-CoV-2 interacts with the angiotensin-converting enzyme 2 (ACE2) receptor on bronchial and alveolar epithelial cells through its spike (S) protein receptor-binding domain (RBD), which is subsequently primed by a specific cellular serine protease, transmembrane protease serine 2 (TMPRSS2), to gain entry<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. Analysis of transcripts encoding ACE2 and TMPRSS2 by single-cell RNA sequencing has shown that these transcripts are co-expressed in various cell types<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>, and from autopsy studies SARS-CoV-2 can be detected in multiple organs, including the lungs, pharynx, heart, liver, brain and kidneys<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p><sec id="Sec3"><title>Innate immune responses</title><p id="Par7">Emerging evidence suggests that the immune response to SARS-CoV-2 is similar in several aspects to the response to SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV), the two coronaviruses responsible for the 2002&#x02013;2004 SARS outbreak and the 2012 MERS outbreak that originated in China and Saudi Arabia, respectively<sup><xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref></sup>. Like SARS-CoV and MERS-CoV, SARS-CoV-2 suppresses activation of the innate immune system, including dendritic cells<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>, and dampens antiviral type I and type&#x000a0;III interferon responses<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. This ability of SARS-CoV-2 to subvert the innate immune response may explain the protracted incubation or presymptomatic period of 2&#x02013;12&#x000a0;days for COVID-19 relative to the 1&#x02013;4-day incubation period for influenza<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Thus, uncontrolled SARS-CoV-2 replication in the early phase of infection resulting from innate immune suppression probably underpins the ensuing dysregulated inflammatory responses<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>, particularly in severe cases of COVID-19. Such cases are characterized by markedly increased numbers of inflammatory monocytes and neutrophils in blood<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> and CD14<sup>+</sup>CD16<sup>+</sup> monocyte-derived macrophages in the airway<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>, and increased systemic levels of inflammatory cytokines and chemokines<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. A failure to accomplish early control of SARS-CoV-2 infection in the respiratory tract likely results in high viral burden and dysregulated, potentially lethal, inflammatory responses and immunopathology, including <xref rid="Glos1" ref-type="list">acute respiratory distress syndrome</xref>. For this reason, seniors and those with co-morbidities may be particularly prone to COVID-19 owing to <xref rid="Glos2" ref-type="list">immunosenescence</xref> and their propensity to mount exaggerated inflammatory responses<sup><xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref></sup>. Besides the consideration of vaccine-induced adaptive immunity discussed later, inclusion of the recently emerged concept of <xref rid="Glos3" ref-type="list">trained immunity</xref> (Box&#x000a0;<xref rid="Sec4" ref-type="sec">1</xref>) in COVID-19 vaccine design might further bolster protection, particularly in the early phases of infection.</p></sec><sec id="Sec4"><boxed-text><label>Box 1 Trained immunity as a potential COVID-19 vaccine strategy</label><p id="Par8">Innate immune memory (also known as trained immunity) is a recently recognized component of immunological memory that has implications for vaccine strategies<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR168">168</xref>,<xref ref-type="bibr" rid="CR169">169</xref></sup>. Several live attenuated human vaccines induce trained immunity that can mediate non-specific protective responses to heterologous infections in addition to pathogen-specific adaptive immune memory<sup><xref ref-type="bibr" rid="CR168">168</xref>&#x02013;<xref ref-type="bibr" rid="CR170">170</xref></sup>. The most well-studied human vaccine that induces trained immunity is the bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG) vaccine against tuberculosis<sup><xref ref-type="bibr" rid="CR171">171</xref></sup>. BCG vaccination endows circulating monocytes with characteristics of trained immunity through epigenetic and metabolic rewiring of myeloid progenitors in the bone marrow<sup><xref ref-type="bibr" rid="CR169">169</xref>,<xref ref-type="bibr" rid="CR172">172</xref>,<xref ref-type="bibr" rid="CR173">173</xref></sup>. These trained monocytes enhance protection against heterologous infections, including respiratory viral infection<sup><xref ref-type="bibr" rid="CR174">174</xref>&#x02013;<xref ref-type="bibr" rid="CR176">176</xref></sup>. BCG may therefore offer a level of protection from coronavirus disease 2019 (COVID-19), which might be supported by the observed inverse correlation between universal BCG vaccination and COVID-19 fatalities<sup><xref ref-type="bibr" rid="CR177">177</xref></sup>. Several clinical trials are under way to assess the effects of BCG or measles vaccination on COVID-19 (ref.<sup><xref ref-type="bibr" rid="CR178">178</xref></sup>).</p><p id="Par9">A COVID-19 vaccine that can induce trained immunity might enhance early viral control by overcoming virus-imposed innate immune suppression and facilitating adaptive immune activation. The early timing of action by trained immunity is of importance as the overproduction of cytokines by macrophages at later stages of COVID-19 can contribute to immunopathology. Although it remains to be understood how to best harness trained immunity for COVID-19 vaccine strategies, recent evidence suggests that routes of microbial exposure or vaccination determine the tissue distribution of trained immunity<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR169">169</xref></sup>. As respiratory mucosal immunity is key to early clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), inducing trained immunity in alveolar macrophages and other innate cells<sup><xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR179">179</xref>&#x02013;<xref ref-type="bibr" rid="CR181">181</xref></sup> through respiratory mucosal vaccination could be an effective strategy. Indeed, a human serotype 5 adenovirus-vectored vaccine delivered to the respiratory mucosa induces memory alveolar macrophages capable of trained immunity against heterologous infections<sup><xref ref-type="bibr" rid="CR85">85</xref></sup>. However, it is unclear whether lung memory macrophages may be replaced by inflammatory monocytes in response to SARS-CoV-2.</p></boxed-text></sec><sec id="Sec5"><title>Antibody responses</title><p id="Par10">IgM and IgG antibodies to SARS-CoV-2 are detectable within 1&#x02013;2 weeks after the onset of symptoms in most infected individuals<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Although the relationship between neutralizing antibodies and antigen-specific T cells and disease severity and clinical outcomes remains to be understood, high levels of neutralizing antibodies have been observed in convalescent individuals<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, which correlate with T cell responses, particularly those of CD4<sup>+</sup> T cells<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, and seem to offer some benefits in studies of treatment with convalescent plasma<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Recent studies indicate that the magnitude of neutralizing antibody responses is positively correlated with disease severity<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Thus, whereas antibody responses wane within weeks after infection in most people infected with SARS-CoV-2 (ref.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>), which is a feature of antibody responses to other &#x02018;common cold&#x02019; coronaviruses<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, the magnitude of the neutralizing antibody response in asymptomatic individuals is not only smaller but also decreases faster than in symptomatic individuals<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par11">The major target of neutralizing antibodies to coronaviruses is the S protein, which is composed of S1 and S2 domains. S1 is membrane distal and contains the RBD that binds to the cellular receptor ACE2. S2 is membrane proximal and has a role in membrane fusion<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. The S proteins of SARS-CoV and SARS-CoV-2 are 88% identical and both bind to ACE2 with high affinity<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Certain monoclonal and polyclonal antibodies raised to the S protein of SARS-CoV can cross-neutralize SARS-CoV-2 (refs<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>). Antibodies that bind to the S1 RBD block its interaction with ACE2, whereas those that bind to other regions of S1 and S2 can inhibit conformational change of the S protein and block membrane fusion, respectively<sup><xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref></sup>.</p><p id="Par12">During natural immune responses to SARS-CoV-2, high titres of antibodies are also generated against nucleoprotein (N) &#x02014; the most abundant viral protein<sup><xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup>. Although antibodies to N are unlikely to neutralize the virus, they have been reported to provide protection against mouse hepatitis virus, a coronavirus of mice. Notably, these antibodies were IgG2a, indicating that they may exert protection through <xref rid="Glos4" ref-type="list">Fc-mediated effector functions</xref> rather than direct virus neutralization<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. Somewhat unusually, several studies have reported that IgA responses to S protein peak earlier than IgM responses and are more pronounced, which makes IgA a potentially attractive target for antibody-based diagnostic assays<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. The mechanistic basis of this early induction of S-specific IgA is not yet clear.</p><p id="Par13">We do not yet understand the durability of the antibody responses to SARS-CoV-2. However, previous longitudinal studies of patients with SARS-CoV infection reported substantial waning of neutralizing antibody titres between 1 year and 2 years after infection<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. This is consistent with classical studies showing a relatively rapid waning of antibodies to the seasonal coronavirus 229E<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. There are currently no immune correlates of protection for SARS-CoV-2 or other human coroanviruses. Thus, it is unclear what titre of neutralizing antibodies is sufficient to confer protection against infection. Establishing such correlates will be essential to guide the development of effective COVID-19 vaccines.</p></sec><sec id="Sec6"><title>T cell-mediated immunity</title><p id="Par14">Whereas the current successful human antiviral vaccines, such as influenza and measles vaccines, depend largely on the induction of antibody responses, emerging evidence suggests the requirement of both antibody-mediated and T cell-mediated immunity for effective protection against SARS-CoV-2 (refs<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>). It is well known that CD4<sup>+</sup> T cell help is important for optimal antibody responses and for CD8<sup>+</sup> T cell activation in host defence<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Furthermore, if neutralizing antibody-mediated protection is incomplete, cytotoxic CD8<sup>+</sup> T cells are crucial for viral clearance<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. One study found that among people who had recovered from COVID-19, 100% had S protein-specific CD4<sup>+</sup> T cells in the circulation and 70% had S protein-specific CD8<sup>+</sup> T cells in the circulation<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, and preclinical studies show a protective role of T cells in host defence against SARS-CoV<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>.</p><p id="Par15">The 2&#x02013;12-day incubation or presymptomatic period of SARS-CoV-2 infection is associated not only with virus-mediated innate immune suppression but also with delayed activation of T cells, particularly CD8<sup>+</sup> T cells<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>, as is the case for SARS and MERS. People who have recovered from COVID-19 seem to have high levels of both neutralizing antibodies and T cells, and, compared with severe cases, milder cases of COVID-19 have greater numbers of memory CD8<sup>+</sup> T cells in the respiratory tract<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>. Evidence suggests that the induction of such lung tissue-resident memory T cells (T<sub>RM</sub> cells) will depend on the route of vaccination. <xref rid="Glos5" ref-type="list">Respiratory mucosal vaccination</xref> induces strong lung T<sub>RM</sub> cell responses, whereas <xref rid="Glos6" ref-type="list">parenteral vaccination</xref> fails to do so<sup><xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref></sup>. Experimentally, the airway T<sub>RM</sub> cells elicited by respiratory mucosal vaccination offered robust protection against SARS-CoV infection<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>.</p><p id="Par16">The T helper cell (T<sub>H</sub> cell) phenotype of vaccine-induced T cells is also relevant to the protection they mediate. Less severe cases of SARS were associated with accelerated induction of a T<sub>H</sub>1 cell response<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, whereas T<sub>H</sub>2 cell responses have been associated with enhancement of lung disease following infection in hosts parenterally vaccinated with inactivated SARS-CoV viral vaccines<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>. Thus, COVID-19 vaccine-induced T<sub>RM</sub> cells should have a T<sub>H</sub>1 cell-like phenotype.</p><p id="Par17">These lines of evidence, together with data suggesting that T cell-mediated immunity generally is a more reliable correlate of vaccine protection than antibody titres in seniors<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, strongly support the inclusion of T cell responses in COVID-19 vaccine design<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>.</p></sec><sec id="Sec7"><title>Pre-existing cross-reactive immunity</title><p id="Par18">Emerging evidence indicates that CD4<sup>+</sup> T cells in 35% of healthy individuals not exposed to SARS-CoV-2 recognize the SARS-CoV-2 S protein and that CD4<sup>+</sup> T cells in 40&#x02013;60% of unexposed individuals are reactive to SARS-CoV-2 proteins other than S protein<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. This indicates that there is cross-reactivity between CD4<sup>+</sup> T cells specific for SARS-CoV-2 and CD4<sup>+</sup> T cells specific for human common cold coronaviruses, SARS-CoV and animal betacoronaviruses<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref></sup>. There are four human coronaviruses &#x02014; 229E, NL63, OC43 and HKU1 &#x02014; that account for ~15% of common colds in humans<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Adults may be infected with one of these on average every 2&#x02013;3 years, such that there could be a degree of pre-existing cross-reactive immunity to SARS-CoV-2 antigens in these people, which offers a potential explanation for differing susceptibility to SARS-CoV-2 infection. In addition to understanding the relationship between such pre-existing immunity to human coronaviruses and host defence against SARS-CoV-2, it will also be important to consider the contribution of COVID-19 vaccine-boosted cross-reactive immune responses to vaccine-induced protective immunity.</p><p id="Par19">Importantly, whereas CD4<sup>+</sup> T cells from patients with COVID-19 equally recognize the S1 and S2 subunits of SARS-CoV-2, cross-reactive CD4<sup>+</sup> T cells from unexposed individuals recognize the S2 subunit<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. CD4<sup>+</sup> T cells from patients with COVID-19 cross-react strongly with S2 subunits of the human coronaviruses OC43 and 229E. More than 90% of tested healthy adults also have IgG antibodies specific for all four human common cold coronaviruses<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. However, similarly to&#x000a0;antibody responses to SARS-CoV and SARS-CoV-2, antibody responses to human coronaviruses wane rapidly within months after infection. Therefore, control of reinfection with human coronaviruses seems mainly to be antibody independent but T cell dependent<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par20">As coronavirus cross-reactive T cells can be specific for both structural and non-structural viral proteins<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>, the extent of vaccine-boosted cross-reactive T cell responses induced by most protein subunit and recombinant viral-vectored COVID-19 vaccines, which are currently based only on the S protein, will be different from those boosted by multivalent COVID-19 vaccines such as those based on inactivated SARS-CoV-2 virus. One exception could be the use of live attenuated SARS-CoV-2 vaccines as the pre-existing cross-reactive immunity may limit the potency of such vaccines. Finally, it is noteworthy that the significant presence of cross-reactive immunity in some individuals calls for consideration of stratifying clinical trial participants receiving candidate COVID-19 vaccines according to their status of pre-existing coronavirus immunity.</p></sec><sec id="Sec8"><title>Antibody-dependent enhancement of disease</title><p id="Par21">A potential barrier to the development of safe and efficacious COVID-19 vaccines (Box&#x000a0;<xref rid="Sec9" ref-type="sec">2</xref>) is the risk that insufficient titres of neutralizing antibodies might trigger <xref rid="Glos7" ref-type="list">antibody-dependent enhancement</xref> (ADE) of disease. ADE is most classically associated with dengue virus, whereby cross-reactive but subneutralizing concentrations of antibodies to one virus serotype enhance infection with another serotype in Fc&#x003b3; receptor (Fc&#x003b3;R)-bearing cells, including macrophages<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. A common property among viruses that cause ADE is an ability to replicate in macrophages and/or cause them to respond abnormally. Although macrophages do not seem to be a major target of SARS-CoV-2 infection, and the expression of ACE2 on different monocyte and macrophage populations is highly variable, previous data regarding SARS-CoV suggest that Fc&#x003b3;Rs can facilitate uptake of the virus into macrophages and B cells<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. Cytokine profiles from patients infected with SARS-CoV-2 resemble those in <xref rid="Glos8" ref-type="list">macrophage activation syndrome</xref> and are characterized by high levels of inflammatory cytokines and chemokines<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR64">64</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref></sup>. Furthermore, patients with symptomatic COVID-19 are reported to produce IgG antibodies with reduced fucosylation levels, which in turn promotes their interaction with activating Fc&#x003b3;RIIIa<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>.</p><p id="Par22">The evidence for ADE in the context of SARS-CoV infection is circumstantial. Correlations between antibody titres and infection severity have been reported, but it is unclear whether high antibody titres contribute to disease or whether severe infections elicit higher antibody titres<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. Also, macrophages treated in vitro with serum from patients with SARS had exaggerated inflammatory cytokine profiles<sup><xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>.</p><p id="Par23">ADE has been reported in some preclinical animal models vaccinated with experimental SARS-CoV vaccines. Ferrets vaccinated with a modified vaccinia virus Ankara (MVA) vaccine expressing full-length S protein had increased infection and hepatitis following challenge<sup><xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR72">72</xref></sup>. Antibodies to S protein were reported to induce acute lung injury in experimentally infected macaques on the basis of histological examination<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. By contrast, hamsters vaccinated with recombinant, full-length SARS-CoV S protein were protected against infection despite the ability of antibodies to mediate entry of SARS-CoV into B cells through Fc&#x003b3;RII (ref.<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>).</p><p id="Par24">Whether ADE occurs in the context of SARS-CoV-2 infection remains unclear but warrants further investigation, focusing directly on whether antibodies increase disease severity and, if so, characterizing the specific properties of these antibodies. What seems clear is that high levels of neutralizing antibodies can mediate protection. Defining the titres of neutralizing antibodies that are protective, ensuring that COVID-19 vaccines can achieve these titres and avoiding waning of antibodies to subneutralizing levels through frequent boosting will be important to minimize the possibility of ADE. Rationally designed COVID-19 vaccines that omit ADE-inducing, non-neutralizing or weakly neutralizing epitopes in favour of those known to mediate protective responses may also minimize the likelihood of disease enhancement. Finally, there is also evidence from mouse models of dengue virus infection that antiviral T cells help to dampen ADE of disease<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. Therefore, a vaccine strategy designed to induce both neutralizing antibodies and robust T cell-mediated immunity may help to mitigate the risk of ADE.</p></sec><sec id="Sec9"><boxed-text><label>Box 2 Safety considerations for COVID-19 vaccines</label><p id="Par25">As most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are asymptomatic or develop only mild symptoms and coronavirus disease 2019 (COVID-19) vaccines are being developed towards an ultimate goal of global mass immunization, vaccine safety is of paramount importance. Any indication of a lack of safety consideration could also fuel the antivaccination movement and vaccine hesitancy, which would jeopardize the desired effect of achieving herd immunity. In this regard, most of the current COVID-19 vaccine clinical trials were initially conducted in healthy adults aged 55 years or younger, with only some later stage trials including seniors<sup><xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR99">99</xref>,<xref ref-type="bibr" rid="CR115">115</xref>,<xref ref-type="bibr" rid="CR146">146</xref>&#x02013;<xref ref-type="bibr" rid="CR148">148</xref></sup>. The highly susceptible elderly populations and those with underlying medical conditions are in particular need of highly safe and effective vaccines. It remains largely unclear whether any of the initially trialled COVID-19 vaccines will be safe for both young children and seniors in both the short term and the long term. It remains likely that a different vaccine strategy with proven safety and efficacy profiles might be required for protection in seniors.</p><p id="Par26">The safety of a vaccine is generally determined by the nature of the vaccine platform, the choice of adjuvant, the mode and route of vaccine administration, the age of vaccinees and the status of pre-existing vaccine immunity<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. For example, replicating live attenuated virus or viral-vectored vaccines may not be safe for a respiratory mucosal route of vaccination. Neither are certain immune adjuvants such as alum and bacterial-derived proteins. When a prime&#x02013;boost immunization strategy is required, adverse events are generally more frequent and intense following the booster vaccination<sup><xref ref-type="bibr" rid="CR115">115</xref></sup>. Vaccine strategies for COVID-19, as for some other respiratory viral infections, require additional safety considerations related to the possibility of antibody-dependent enhancement of disease and the role of overproduction of proinflammatory cytokines in lung immunopathology. The latter pertains particularly to the application of respiratory mucosal vaccine strategies.</p></boxed-text></sec></sec><sec id="Sec10"><title>Vaccine design</title><p id="Par27">Vaccine design concerns the selection of antigens, vaccine platforms, and vaccination routes and regimen. The choice of vaccine platform determines the relative immunogenic strength of vaccine-derived viral antigens, whether an immune adjuvant is required and the nature of protective immunity. These attributes also determine the suitability of a vaccine for a particular route of vaccination, and whether a prime&#x02013;boost vaccination regimen is required to increase vaccine-mediated protective immunity and its durability. Furthermore, the selection of live attenuated viral vaccines or a respiratory mucosal route of vaccination will require more stringent safety testing (Box&#x000a0;<xref rid="Sec9" ref-type="sec">2</xref>).</p><sec id="Sec11"><title>Selection of SARS-CoV-2 antigens</title><p id="Par28">The structural proteins present in the infectious virion include S protein, N protein, matrix (M) protein and envelope (E) protein. The N protein coats the large positive-stranded RNA genome, which is encased in a lipid envelope derived from the host cell membrane, into which the other three proteins (S, M and E) are inserted. In the case of SARS-CoV, it has been shown that only antibodies directed to S protein can neutralize the virus and prevent infection<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. As a result, all SARS-CoV-2 vaccines in development include at least a portion of the S protein. These may be restricted to only the S1 domain or the RBD.</p><p id="Par29">Non-neutralizing antibodies to both S protein and the other exposed proteins (E and M) are generated. As there is a suspected role of these non-neutralizing antibodies, as well as weakly neutralizing antibodies, in ADE of disease, the inclusion of other structural (N) and/or non-structural proteins as vaccine antigens may help to create a more balanced response involving both humoral and T cell-mediated immunity. These could be highly expressed proteins such as N protein or highly conserved functional proteins that have a crucial role in the viral life cycle. For example, inclusion of viral enzymes such as the RNA-dependent RNA polymerase in a vaccine design may ensure that it targets all emerging variant strains, as these proteins are highly conserved<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>, even across other bat-derived coronaviruses that could emerge as a threat to humans in the&#x000a0;future.</p></sec><sec id="Sec12"><title>Vaccine platforms</title><p id="Par30">In general, vaccine platforms are divided into six categories: live attenuated virus, recombinant viral-vectored vaccines that are bioengineered to express target pathogen antigens in vivo, inactivated or killed virus, protein subunit vaccines, <xref rid="Glos9" ref-type="list">virus-like particles</xref> (VLPs) and nucleic acid-based (DNA or mRNA) vaccines. In broad terms, vaccines require two components: antigens from the target pathogen that are provided to or generated by the vaccine recipient; and an infection signal (such as a pathogen-associated molecular pattern or damage-associated molecular pattern) that alerts and activates the host immune system. Live attenuated vaccines can naturally provide both of these components, whereas non-viral vaccine platforms can provide the antigens but often require the artificial provision of signals to alert the immune system known as <xref rid="Glos10" ref-type="list">adjuvants</xref>. Typically, these non-viral vaccine platforms require multiple vaccinations to induce protective immunity, whereas live virus-based vaccines have the ability to provide &#x02018;one-shot&#x02019; immunity. Similarly to non-viral platforms, killed virus vaccines sometimes require the inclusion of an adjuvant and repeated administration for full efficacy<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. There are immunological pros and cons to each of these technologies as discussed later (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Immunological properties of major COVID-19 candidate vaccine platforms</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Vaccine platform</th><th rowspan="2">SARS-CoV-2 antigens</th><th rowspan="2">Neutralizing antibody response</th><th colspan="3">T cell response</th><th rowspan="2">Pre-existing antivector immunity</th><th rowspan="2">Route of vaccination</th><th rowspan="2">Overall immunogenicity</th><th rowspan="2">Other attributes</th></tr><tr><th>CD4<sup>+</sup> T<sub>H</sub> cells</th><th>CD8<sup>+</sup> T cells</th><th>Lung T<sub>RM</sub> cells</th></tr></thead><tbody><tr><td colspan="10"><bold><italic>Viral-vectored vaccines</italic></bold></td></tr><tr><td>Ad5 (non-replicating)</td><td>S protein</td><td>Quality and durability affected by pre-existing antivector immunity</td><td>T<sub>H</sub>1 cell</td><td>Potent response; negative effects from pre-existing antivector immunity</td><td>Induced by RM but not IM route</td><td>High, age-dependent, prevalence in blood; low prevalence in respiratory tract</td><td>Parenteral (IM) in clinical trials</td><td>Strong with single delivery but hindered by pre-existing antivector immunity</td><td>Ample human safety data; RM delivery helps bypass antivector immunity; can be delivered by inhaled aerosol</td></tr><tr><td>Ad26 (non-replicating)</td><td>S protein</td><td>Quality and durability affected by pre-existing antivector immunity</td><td>T<sub>H</sub>1 cell</td><td>Moderate response; negative effects from pre-existing antivector immunity</td><td>Induced by RM but not IM route</td><td>Medium prevalence</td><td>Parenteral (IM) in planned clinical trials</td><td>Weak; requires repeated or heterologous boost vaccination</td><td>Established human safety from HIV and Ebola vaccine trials; RM delivery helps bypass antivector immunity</td></tr><tr><td>ChAd (non-replicating)</td><td>S protein</td><td>Unimpeded owing to lack of pre-existing antivector immunity</td><td>T<sub>H</sub>1 cell</td><td>Potent response</td><td>Induced by RM but not IM route</td><td>Very low prevalence</td><td>Parenteral (IM) in clinical trials</td><td>Strong with single delivery</td><td>Well-established human safety data; amenable to RM delivery; can be used as a stand-alone vaccine or in prime&#x02013;boost regimens</td></tr><tr><td>VSV (replicating)</td><td>S protein</td><td>Unimpeded owing to lack of pre-existing antivector immunity</td><td>T<sub>H</sub>1 cell</td><td>Response not as strong as for Ad5 or ChAd when used as a stand-alone vaccine; strong T cell booster</td><td>Not induced by IM route</td><td>None</td><td>Parenteral (IM) in previous successful Ebola vaccine trials</td><td>Good with single delivery</td><td>Successfully licensed platform for Ebola; not known whether it protects against RM viral pathogens</td></tr><tr><td>Measles and influenza viruses (replicating)</td><td>S protein?</td><td>Quality and durability depend on whether there is pre-existing antivector immunity and vaccination route</td><td>T<sub>H</sub>1 cell</td><td>Good response when delivered via RM route</td><td>Not induced by parenteral route</td><td>High prevalence owing to vaccination and natural infection</td><td>Parenteral or RM</td><td>Weak relative to adenovirus vectors</td><td>Not extensively tested in humans; potential recombination of live attenuated influenza vectors in the lung delivered via RM route</td></tr><tr><td colspan="10"><bold><italic>Other vaccines</italic></bold></td></tr><tr><td>mRNA-based vaccine</td><td>S protein or RBD encapsulated in lipid nanoparticle</td><td>Unimpeded owing to lack of pre-existing antivector immunity</td><td>T<sub>H</sub>1 cell or T<sub>H</sub>2 cell depending on adjuvant</td><td>Depends on choice of adjuvant and formulation</td><td>Not induced by parenteral route</td><td>None</td><td>Parenteral (IM) in clinical trials</td><td>Requires repeated delivery</td><td>Adjuvant required; unclear whether it is amenable to RM vaccination</td></tr><tr><td>DNA-based vaccine</td><td>S protein</td><td>Unimpeded owing to lack of pre-existing antivector immunity</td><td>T<sub>H</sub>1 cell</td><td>Response not as strong as for some of the viral vectors</td><td>Not induced</td><td>None</td><td>Parenteral (IM) in clinical trials</td><td>Weaker than mRNA-based vaccine; requires repeated delivery</td><td>Adjuvant required; not amenable to RM vaccination</td></tr><tr><td>Live attenuated virus</td><td>Multiple viral antigens</td><td>Strong induction</td><td>T<sub>H</sub>1 cell</td><td>Strong response</td><td>Induced by RM but not IM route</td><td>No cross-reactive antibodies; cross-reactive T cells from seasonal coronavirus infections</td><td>Parenteral (SC)</td><td>Requires only a single delivery</td><td>Extensive safety testing required for potential recombination with wild-type virus</td></tr><tr><td>Inactivated virus</td><td>Multiple viral antigens</td><td>Strong induction</td><td>T<sub>H</sub>1 cell or T<sub>H</sub>2 cell depending on adjuvant</td><td>Weak response</td><td>Not induced</td><td>None</td><td>Parenteral (IM)</td><td>Weak; requires repeated vaccination</td><td>Adjuvant required; alum often used, which enhances T<sub>H</sub>2 cell responses possibly involved in ADE</td></tr><tr><td>Protein subunit vaccine</td><td>S protein or RBD</td><td>Strong induction</td><td>T<sub>H</sub>1 cell or T<sub>H</sub>2 cell depending on adjuvant</td><td>Weak response</td><td>Not induced</td><td>None</td><td>Parenteral (IM) in clinical trials</td><td>Weak; requires repeated vaccination</td><td>Adjuvant required; mostly unsuitable for RM vaccination</td></tr><tr><td>Virus-like particle</td><td>Multiple viral antigens</td><td>Strong induction</td><td>T<sub>H</sub>1 cell or T<sub>H</sub>2 cell depending on adjuvant</td><td>Weak response</td><td>Not induced</td><td>None</td><td>Parenteral (IM) or RM</td><td>Weak, but greater than for protein subunits; requires repeated vaccination</td><td>Well-established platform for several commercial human vaccines (hepatitis B and HPV vaccines); adjuvant required</td></tr></tbody></table><table-wrap-foot><p>Ad5, human serotype 5 adenovirus; Ad26, human serotype 26 adenovirus; ADE, antibody-dependent enhancement; ChAd, chimpanzee adenovirus; COVID-19, coronavirus disease 2019; HPV, human papillomavirus; IM, intramuscular; RBD, receptor-binding domain; RM, respiratory mucosal; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S protein, spike protein; SC, subcutaneous; T<sub>H</sub> cell, T helper cell; T<sub>RM</sub> cell, resident memory T cell; VSV, vesicular stomatitis virus.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Vaccination routes and regimens</title><p id="Par31">In addition to the careful selection of vaccine antigens and platform, the route of vaccination is an integral consideration of vaccine strategies<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR79">79</xref></sup>. This is particularly important for mucosal pathogens such as SARS-CoV-2 and those pathogens against which optimal protection requires not only neutralizing antibodies but also innate and adaptive cellular immunity<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR80">80</xref></sup>. The best window of opportunity for SARS-CoV-2 control and clearance is the asymptomatic or presymptomatic period of COVID-19 (2&#x02013;12 days), which is likely to require all of the immune protective elements to be present within the respiratory mucosa before viral entry<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. The route of vaccination has a crucial role in determining this<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>. Protective IgG antibodies induced by parenteral vaccination readily appear at the respiratory mucosa, this being the primary mechanism by which intramuscular injection of measles or influenza vaccine offers protection in humans. However, this route of vaccination is unable to effectively induce mucosal IgA antibodies or T<sub>RM</sub> cells in the lungs<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>. By comparison, the respiratory mucosal route of vaccination is adept at inducing antibodies and T<sub>RM</sub> cells in the respiratory mucosa, as well as macrophage-mediated trained immunity<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR80">80</xref>&#x02013;<xref ref-type="bibr" rid="CR85">85</xref></sup> (Box&#x000a0;<xref rid="Sec4" ref-type="sec">1</xref>). Inactivated virus, protein subunit and nucleic acid vaccines cannot be administered by the respiratory mucosal route owing to their requirement for potentially unsafe immune adjuvants and repeated delivery (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). By contrast, recombinant viral-vectored vaccines, particularly those using human serotype 5 adenovirus (Ad5) or chimpanzee-derived adenovirus (ChAd), are safe and highly effective for respiratory mucosal vaccination<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>.</p><p id="Par32">Often, weakly immunogenic vaccines based on inactivated virus, protein subunits, nucleic acids or viral vectors such as Ad26 require a repeated homologous vaccination regimen to be effective. Indeed, most current human vaccines require repeated doses. As it is not yet known which COVID-19 vaccine strategy will be used or for how long the vaccine-induced protection may last in humans, it remains possible that a <xref rid="Glos11" ref-type="list">homologous or heterologous prime&#x02013;boost vaccination</xref> regimen will be required to sustain protection, even with robust stand-alone platforms such as ChAd. The same or a different route may be used for the repeated vaccine delivery.</p></sec></sec><sec id="Sec14"><title>Major COVID-19 vaccine candidates</title><p id="Par33">As of 31 July 2020, there were 27 vaccine candidates for COVID-19 in clinical evaluation and 139 vaccines in preclinical development<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Of the 27 vaccines undergoing clinical evaluation (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), the three lead candidates are viral-vectored and mRNA-based vaccines that entered clinical trials in China, the UK and the USA in mid-March 2020. Clinical trials for the remaining 24 candidates are currently recruiting volunteers, and a couple of other candidates are also about to enter clinical trials (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Preclinical evaluation of candidate vaccines requires the use of relevant animal models of COVID-19 (Box&#x000a0;<xref rid="Sec15" ref-type="sec">3</xref>). Conventionally, the safety, immunogenicity and protective efficacy of experimental vaccines are rigorously evaluated and established in animal models first before clinical trials are begun. In the case of pandemic vaccine development, however, the preclinical and clinical stages of vaccine development are compressed and move forwards in parallel.<table-wrap id="Tab2"><label>Table 2</label><caption><p>COVID-19 vaccine candidates in or entering clinical trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Vaccine</th><th>Platform</th><th>Developer</th><th>Clinical trial phase</th><th>Immunization attributes</th><th>Preclinical data</th><th>Clinical data</th><th>Clinical Trial registrations</th><th>Refs</th></tr></thead><tbody><tr><td>ChAdOx1 nCov-19 (AZD-1222)<sup>a</sup></td><td>ChAd-vectored, non-replicating</td><td>University of Oxford, AstraZeneca</td><td>Phases I&#x02013;III in UK, South Africa, USA and Brazil</td><td>Expressing S protein; single dose or two repeated doses of IM injection</td><td>Published data showing prevention of pneumonia but not transmission in NHPs</td><td>Published data showing safety and good induction of neutralizing antibodies and T cell activation in &#x0003e;90% of vaccinees</td><td>ISRCTN89951424, EudraCT 2020-001228-32, PACTR202006922165132, EudraCT 2020-001072-15, NCT04324606</td><td><sup><xref ref-type="bibr" rid="CR114">114</xref>,<xref ref-type="bibr" rid="CR115">115</xref></sup></td></tr><tr><td>Ad5-nCoV</td><td>Ad5-vectored, non-replicating</td><td>CanSino Biologics Inc., Beijing Institute of Biotechnology</td><td>Phases I and II; phase II studies in China and Canada</td><td>Expressing S protein; single dose of IM injection</td><td>NA</td><td>Published data showing high dose unsafe, low and medium doses elicit neutralizing antibodies in ~50&#x02013;60% of vaccinees; antibody levels negatively associated with pre-existing antivector immunity and age (&#x0003e;55 years)</td><td>ChiCTR2000031781, ChiCTR2000030906, NCT04341389</td><td><sup><xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR99">99</xref></sup></td></tr><tr><td>mRNA-1273<sup>a</sup></td><td>Lipid nanoparticle&#x02013;mRNA</td><td>Moderna, NIAID</td><td>Phases I&#x02013;III in USA</td><td>Expressing S protein; two repeated doses of IM injection</td><td>Published report showing induction of neutralizing antibodies and CD8<sup>+</sup> T cells, as well as protection, in mouse models</td><td>Published data showing safety, but highest dose causes severe AEs in 20% of vaccinees; induction of neutralizing antibodies in 100% of vaccinees and CD4<sup>+</sup> T cell responses in some</td><td>NCT04405076, NCT04283461, NCT04470427</td><td><sup><xref ref-type="bibr" rid="CR145">145</xref>,<xref ref-type="bibr" rid="CR146">146</xref></sup></td></tr><tr><td>PiCoVacc</td><td>Inactivated SARS-CoV-2</td><td>Sinovac Biotech</td><td>Phases I&#x02013;III; phase III in China and Brazil</td><td>Multiple viral antigens; two repeated doses of IM injection</td><td>Published data from NHP model showing protection</td><td>Interim phase I/II information released to indicate safety and immunogenicity</td><td>NCT04456595, NCT04383574, NCT04352608</td><td><sup><xref ref-type="bibr" rid="CR126">126</xref></sup></td></tr><tr><td>NVX-CoV2373<sup>a</sup></td><td>Protein subunit</td><td>Novavax</td><td>Phases I and II in Australia</td><td>Recombinant S protein; two repeated doses of IM injection</td><td>Unpublished information indicates high levels of S-specific neutralizing antibodies</td><td>NA</td><td>NCT04368988</td><td>&#x02013;</td></tr><tr><td>BNT162b1<sup>a</sup></td><td>Lipid nanoparticle&#x02013;mRNA</td><td>BioNTech, Pfizer, Fosun Pharma</td><td>Phases I&#x02013;III; dose- and candidate-finding in Germany, USA and China</td><td>RBD of S protein; two repeated doses of IM injection</td><td>Published data from mouse model showing strong antibody and T cell responses</td><td>Submitted report indicating safety, high neutralizing antibody titres and T<sub>H</sub>1 cell-type CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses</td><td>NCT04368728, Eudra CT 020-001038-36, ChiCTR2000034825</td><td><sup><xref ref-type="bibr" rid="CR147">147</xref>,<xref ref-type="bibr" rid="CR148">148</xref>,<xref ref-type="bibr" rid="CR166">166</xref></sup></td></tr><tr><td>BBIBP-CorV</td><td>Inactivated SARS-CoV-2</td><td>Sinopharm, Beijing Institute of Biological Products Co. Ltd</td><td>Phases I&#x02013;III in China and United Arab Emirates</td><td>Multiple viral antigens; two repeated doses of IM injection</td><td>Published data from rodents, rabbits and NHP models showing neutralizing antibodies and protection</td><td>Interim information released to indicate safety and high antibody conversion rates in vaccinees</td><td>ChiCTR2000034780, ChiCTR2000032459</td><td><sup><xref ref-type="bibr" rid="CR127">127</xref></sup></td></tr><tr><td>COVID-19 vaccine</td><td>Inactivated SARS-CoV-2</td><td>Sinopharm, Wuhan Institute of Biological Products Co. Ltd</td><td>Phases I&#x02013;III in China</td><td>Multiple viral antigens; two repeated doses of IM injection</td><td>NA</td><td>Interim information released to indicate safety</td><td>ChiCTR2000034780, ChiCTR2000031809</td><td>&#x02013;</td></tr><tr><td>INO-4800<sup>a</sup></td><td>Plasmid DNA</td><td>Inovio Pharmaceuticals, International Vaccine Institute</td><td>Phases I&#x02013;III in USA</td><td>Expressing S protein; two repeated doses of intradermal injection plus electroporation</td><td>Published data showing immunogenicity in mice and guinea pigs</td><td>Interim information released to indicate safety and overall immune responses</td><td>NCT04447781, NCT04336410</td><td><sup><xref ref-type="bibr" rid="CR157">157</xref></sup></td></tr><tr><td>LNP-nCoVsaRNA</td><td>Lipid nanoparticle&#x02013;saRNA</td><td>Imperial College London, Morningside Ventures</td><td>Phases I and II in UK</td><td>Expressing S protein; two repeated doses of IM injection</td><td>Published report showing induction of neutralizing antibodies and T<sub>H</sub>1 cell responses in mouse models</td><td>NA</td><td>ISRCTN17072692</td><td><sup><xref ref-type="bibr" rid="CR167">167</xref></sup></td></tr><tr><td>COVID-19 vaccine</td><td>Inactivated SARS-CoV-2</td><td>Chinese Academy of Medical Sciences</td><td>Phases I and II in China</td><td>Multiple viral antigens; two repeated doses of IM injection</td><td>NA</td><td>NA</td><td>NCT04470609, NCT04412538</td><td>&#x02013;</td></tr><tr><td>CVnCoV</td><td>Lipid nanoparticle&#x02013;mRNA</td><td>CureVac</td><td>Phase I in Germany and Belgium</td><td>Expressing S protein; two repeated doses of IM injection</td><td>Information released suggesting protection in animal models</td><td>NA</td><td>NCT04449276</td><td>&#x02013;</td></tr><tr><td>Gam-COVID-Vac Lyo</td><td>Ad5- or Ad26-vectored, non-replicating</td><td>Gameleya Research Institute</td><td>Phases I and II in Russia</td><td>Single dose and heterologous Ad26 prime&#x02013;Ad5 boost doses of IM injection</td><td>NA</td><td>NA</td><td>NCT04436471, NCT04437875</td><td>&#x02013;</td></tr><tr><td>GX-19</td><td>Plasmid DNA</td><td>Genexine Consortium</td><td>Phases I and II in South Korea</td><td>Expressing S protein; two repeated doses of IM injection</td><td>NA</td><td>NA</td><td>NCT04445389</td><td><bold>&#x02013;</bold></td></tr><tr><td>SCB-2019</td><td>Protein subunit</td><td>Clover Pharmaceuticals, GlaxoSmithKline, Dynavax</td><td>Phase I in Australia</td><td>Trimeric S protein; two repeated doses of IM injection</td><td>Information released suggesting induction of neutralizing antibodies in multiple animal species</td><td>NA</td><td>NCT04405908</td><td>&#x02013;</td></tr><tr><td>COVID-19 vaccine</td><td>Protein subunit</td><td>Anhui Zhifei Longcom Biologic Pharmacy, Chinese Academy of Medical Sciences</td><td>Phases I and II in China</td><td>Dimeric RBD; two or three repeated doses of IM injection</td><td>NA</td><td>NA</td><td>NCT04445194, NCT04466085</td><td>&#x02013;</td></tr><tr><td>ARCoV</td><td>mRNA</td><td>Academy of Military Medical Sciences, Walvax Biotechnology, Suzhou Abogen Biosciences</td><td>Phase I in China</td><td>Expressing S protein; two repeated doses of IM injection?</td><td>Information released suggesting induction of neutralizing antibodies in mice and NHPs</td><td>NA</td><td>ChiCTR2000034112</td><td>&#x02013;</td></tr><tr><td>COVID-19 vaccine</td><td>Plasmid DNA</td><td>AnGes Inc., Osaka University, Takara Bio</td><td>Phases I and II in Japan</td><td>Expressing S protein; two repeated doses of IM injection</td><td>NA</td><td>NA</td><td>JapicCTI-205328, NCT04463472</td><td>&#x02013;</td></tr><tr><td>COVID-19 vaccine</td><td>Virus-like particle</td><td>Medicago, Laval University</td><td>Phase I in Canada</td><td>Multiple viral antigens; two repeated doses of IM injection</td><td>Information released to indicate antibody responses in mice</td><td>NA</td><td>NCT04450004</td><td>&#x02013;</td></tr><tr><td>Lunar-COV19</td><td>Self-replicating mRNA</td><td>Arcturus Therapeutics, Duke-National University of Singapore</td><td>Phases I and II to be launched in Singapore</td><td>Expressing S protein; one dose of IM injection</td><td>Information released to indicate high levels of neutralizing antibodies after single injection</td><td>NA</td><td>NCT04480957</td><td>&#x02013;</td></tr><tr><td>Covaxin</td><td>Inactivated SARS-CoV-2</td><td>Bharat Biotech, Indian Council of Medical Research, National Institute of Virology</td><td>Phases I and II to be launched in India</td><td>Multiple viral antigens; two repeated doses of IM injection</td><td>NA</td><td>NA</td><td>CTRI/2020/07/026300, NCT04471519</td><td><bold>&#x02013;</bold></td></tr><tr><td>ZyCov-D</td><td>Plasmid DNA</td><td>Zydus Cadila</td><td>Phases I and II to be launched in India</td><td>Expressing S protein; three repeated doses of intradermal injection</td><td>Information released to indicate immune responses in several animal species</td><td>NA</td><td>CTRI/2020/07/026352</td><td>&#x02013;</td></tr><tr><td>COVID-19 vaccine</td><td>Protein subunit</td><td>University of Queensland</td><td>Phase I in Australia</td><td>Molecular clamp-stabilized S protein; two repeated doses of IM injection</td><td>Information released to indicate neutralizing antibodies in animal models</td><td>Information released to indicate safety</td><td>ACTRN12620000674932p</td><td>&#x02013;</td></tr><tr><td>Ad26.COV2-S<sup>a</sup></td><td>Ad26-vectored, non-replicating</td><td>Johnson &#x00026; Johnson</td><td>Phases I and II in USA and Belgium</td><td>Expressing S protein; two repeated doses of IM injection</td><td>Published data from NHPs showing induction of robust neutralizing antibodies and protection by single dose</td><td>NA</td><td>NCT04436276</td><td><sup><xref ref-type="bibr" rid="CR110">110</xref></sup></td></tr><tr><td>KBP-COVID-19</td><td>Protein subunit</td><td>Kentucky Bioprocessing Inc.</td><td>Phases I and II in USA</td><td>Recombinant RBD-based protein; two repeated doses of IM injection</td><td>NA</td><td>NA</td><td>NCT04473690</td><td>&#x02013;</td></tr><tr><td>COVID-19 vaccine<sup>a</sup></td><td>VSV-vectored, replicating</td><td>Merck, IAVI</td><td>Phases I and II to be launched in USA?</td><td>Expressing S protein; IM injection</td><td>NA</td><td>NA</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>COVAX19</td><td>Protein subunit</td><td>Vaxine Pty Ltd, Medytox, Central Adelaide Local Health Network</td><td>Phase I in Australia</td><td>Recombinant S protein with Advax-SM adjuvant; single escalating dose of IM injection</td><td>NA</td><td>NA</td><td>NCT04453852</td><td><bold>&#x02013;</bold></td></tr><tr><td>MVC-COV1901</td><td>Protein subunit</td><td>Medigen Vaccine Biologics, Dynavax</td><td>Phase I to be launched in Taiwan</td><td>Recombinant S protein; two repeated doses of IM injection</td><td>Information released indicating induction of neutralizing antibodies and T cells</td><td>NA</td><td>NCT04487210</td><td>&#x02013;</td></tr><tr><td>COVID-19 vaccine</td><td>Plasmid DNA</td><td>Entos Pharmaceuticals</td><td>Phases I and II to be launched in Canada and USA</td><td>Expressing S protein, IM injection</td><td>Information released indicating induction of neutralizing antibodies and T cells</td><td>NA</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><p>Ad5, human serotype 5 adenovirus; Ad26, human serotype 26 adenovirus; AEs, adverse events; ChAd, chimpanzee adenovirus; COVID-19, coronavirus disease 2019; IM, intramuscular; NA, not available; NHP, non-human primate; RBD, receptor-binding domain; saRNA, self-amplifying RNA; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; S protein, spike protein; T<sub>H</sub>1 cell, T helper 1 cell; VSV, vesicular stomatitis virus. <sup>a</sup>Selected for US Operation Warp Speed.</p></table-wrap-foot></table-wrap></p><sec id="Sec15"><boxed-text><label>Box 3 Animal models of COVID-19 for vaccine testing</label><p id="Par34">There is an urgent need to identify suitable animal models for the preclinical evaluation of coronavirus disease 2019 (COVID-19) vaccines<sup><xref ref-type="bibr" rid="CR182">182</xref></sup>. A large number of animal species have differing degrees of susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, depending on the relative binding affinity of the virus to the host angiotensin-converting enzyme 2 (ACE2) receptor or on host protease activities on the S protein<sup><xref ref-type="bibr" rid="CR183">183</xref></sup>.</p><p id="Par35">Among the animal species tested, ACE2 of rhesus macaques has the greatest binding activity for SARS-CoV-2 (ref.<sup><xref ref-type="bibr" rid="CR183">183</xref></sup>). Infected macaques shed SARS-CoV-2 from the upper and the lower respiratory tract but they do not develop the same clinical signs and age-dependent disease severity as humans<sup><xref ref-type="bibr" rid="CR184">184</xref>,<xref ref-type="bibr" rid="CR185">185</xref></sup>. Cats, ferrets and hamsters are also susceptible to SARS-CoV-2 infection. Notably, natural airborne and contact transmissions of SARS-CoV-2 have been reported in cats and hamsters, respectively, but not in ferrets<sup><xref ref-type="bibr" rid="CR186">186</xref></sup>. Hamsters, but not cats and ferrets, manifest severe clinical symptoms. Thus, these animal models are differentially capable of recapitulating relevant aspects of COVID-19.</p><p id="Par36">Mouse models are widely used for vaccine testing owing to their affordability and the availability of immunoreagents and transgenic mouse strains. However, the ACE2 of conventional mice does not bind well to SARS-CoV S protein<sup><xref ref-type="bibr" rid="CR187">187</xref></sup>. Transgenic mice expressing human ACE2 were initially developed and thoroughly characterized for the study of SARS-CoV and have now been shown to support SARS-CoV-2 replication in the lung, and these mice develop interstitial pneumonia similar to humans<sup><xref ref-type="bibr" rid="CR188">188</xref></sup>. Human ACE2-expressing mice that are further humanized to express human HLA genes and/or to have human immune cells will be useful for studying human immune responses and immunodominant epitopes following vaccination and viral infection with SARS-CoV-2. Beyond animal models, of further relevance to human applications is the ongoing ethical debate regarding intentional challenge of vaccinated young people with SARS-CoV-2.</p></boxed-text></sec><sec id="Sec16"><title>Live attenuated viral vaccines</title><p id="Par37">Historically, several successful human vaccines, such as measles vaccine and the bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG) vaccine for tuberculosis (TB), have been based on attenuated strains of the actual pathogen<sup><xref ref-type="bibr" rid="CR86">86</xref></sup>, with loss or mutation of virulence genes through in vitro passage. It is now possible to rationally design attenuated virus strains by mutating or deleting virulence genes. These deletion mutants can often replicate to a limited extent in host cells but lose the ability to cause disease in vivo. Coronaviruses have several genes that are not required for replication and that can be deleted, leading to attenuation in vivo. Deletion of various non-structural proteins, as well as of the structural E protein, has been used as a strategy to engineer vaccine strains of several zoonotic and veterinary coronaviruses<sup><xref ref-type="bibr" rid="CR87">87</xref>&#x02013;<xref ref-type="bibr" rid="CR89">89</xref></sup>. Deletion of the E protein leads to attenuation and generation of an efficacious vaccine strain<sup><xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>, but reversion of the attenuated phenotype has been reported<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>. Deletion of virulence factors may therefore provide a preferred mechanism of attenuation. For example, deletion of the 2&#x02032;-<italic>O</italic>-methylase gene from the SARS-CoV genome removes the ability of the virus to hide its RNA from the host cell proteins MDA5 (also known as IFIH1) and IFIT1, thereby inducing a robust antiviral response in vivo<sup><xref ref-type="bibr" rid="CR91">91</xref></sup>. Another approach to viral attenuation is known as codon deoptimization, whereby the nucleic acid sequence is modified to use suboptimal codons to encode the wild-type amino acid sequence, which considerably slows the translation of the viral protein during infection. This approach can yield a virus that is highly attenuated in vivo but still able to replicate in vitro if the correct viral protein is selected for deoptimization<sup><xref ref-type="bibr" rid="CR92">92</xref>,<xref ref-type="bibr" rid="CR93">93</xref></sup>.</p><p id="Par38">However, the generation of an attenuated strain of a pathogen for use as a vaccine requires demonstration of its inability to revert genetically to become pathogenic (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; Box&#x000a0;<xref rid="Sec9" ref-type="sec">2</xref>). This is particularly challenging in the case of coronaviruses as they are known to recombine in nature<sup><xref ref-type="bibr" rid="CR94">94</xref></sup>, and an attenuated vaccine strain could, in theory, recombine with wild coronaviruses to recreate a pathogenic strain. So far, there are only three attenuated SARS-CoV-2 vaccines generated by codon deoptimization under preclinical development, by Mehmet Ali Aydinlar University in Turkey, Codagenix and Serum Institute of India, and Indian Immunologicals Ltd and Griffith University<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p></sec><sec id="Sec17"><title>Recombinant viral-vectored vaccines</title><p id="Par39">Recombinant viral-vectored vaccines are built on either a replication-deficient viral backbone or an attenuated replication-competent viral backbone that is bioengineered to express antigens derived from the target pathogen. Although only a couple of viral-vectored vaccines have been approved for human use for the control of infections such as Ebola, this platform has been widely investigated and has a well-established track record for infectious diseases and cancer, given its genetic malleability, safety and ability to induce strong T cell responses without the need for an adjuvant<sup><xref ref-type="bibr" rid="CR95">95</xref>,<xref ref-type="bibr" rid="CR96">96</xref></sup>. Some viral vectors, such as Ad5 and ChAd, usually need to be administered only once for protection and have natural tropism for the respiratory mucosa, which means they are amenable to respiratory mucosal vaccination<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>. The technology already exists for their large-scale clinical grade production and storage.</p><p id="Par40">Thus, recombinant viral vectors are the second most common platform for COVID-19 vaccine development, with 4 candidates currently in clinical trials (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), 38 under preclinical development<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> and 3 (ChAdOx1 nCoV-19, Ad26-S and VSV-S) selected for <xref rid="Glos12" ref-type="list">US Operation Warp Speed</xref><sup><xref ref-type="bibr" rid="CR97">97</xref></sup> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The non-replicating viral platforms are mostly based on Ad5 or MVA, and most of these vaccine candidates express the S protein or RBD of SARS-CoV-2. Replication-competent viral vectors are mainly based on the vaccine strains of other human pathogens (such as measles or influenza viruses) or veterinary pathogens (such as vesicular stomatitis virus (VSV)). However, it will be important to consider whether humans have pre-existing immunity against the viral backbone (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Pre-existing antibodies can impair the ability of such vaccines to engage the immune system. Use of viral backbones such as ChAd, for which humans have little to no pre-existing immunity, can help to circumvent this issue<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>.</p><p id="Par41">Ad5-nCOV, which is being developed by the Chinese vaccine company CanSino Biologics, is designed to induce neutralizing antibodies to SARS-CoV-2 S protein following intramuscular injection (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Without published preclinical data, it entered phase I/II clinical trials with three doses of vaccine tested<sup><xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR99">99</xref></sup>. Of note, these doses are 10&#x02013;30&#x000a0;times higher than those used in previous trials of intramuscular vaccines<sup><xref ref-type="bibr" rid="CR100">100</xref>&#x02013;<xref ref-type="bibr" rid="CR102">102</xref></sup>. Whereas the highest dose generated unacceptable toxicity and was dropped from the phase&#x000a0;II study<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>, the smaller doses induced S protein-specific neutralizing antibodies in only 50% of the vaccine recipients<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>. The phase II study largely reaffirms the phase I observations that, although the vaccine induces both antibody and T cell responses, its potency is reduced by pre-existing immunity to Ad5, particularly in elderly participants<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>. Depending on geographical region, 35&#x02013;95% of humans have significant circulating levels of neutralizing antibodies to Ad5 (ref.<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>). This is consistent with the rapidly declining antibody titres observed in a phase II Ad5-Ebola vaccine study<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>. The vaccine is entering further advanced trials in China and Canada, but the efficacy of this strategy is now in question<sup><xref ref-type="bibr" rid="CR105">105</xref></sup>. Another human adenovirus-based COVID-19 vaccine, known as Ad26-S, is being developed by Johnson &#x00026; Johnson, although there is still 40% seroprevalence for Ad26 in humans<sup><xref ref-type="bibr" rid="CR106">106</xref></sup>. As Ad26 is inherently less immunogenic than Ad5 (ref.<sup><xref ref-type="bibr" rid="CR107">107</xref></sup>), effective immunity requires repeated homologous or heterologous vaccination, as has been shown in Ad26-HIV and Ad26-Ebola vaccine studies in humans<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR109">109</xref></sup>. Nevertheless, a single parenteral administration of an Ad26-vectored COVID-19 vaccine (Ad26.COV2.S) offered robust protection in a non-human primate model of SARS-CoV-2 (ref.<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>).</p><p id="Par42">ChAdOx1 nCoV-19 (also known as AZD-1222), which is being developed by Oxford University, UK, and AstraZeneca, is the most clinically advanced COVID-19 vaccine (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Humans have low seroprevalence for ChAd, hence its strong immunogenicity and utility for heterologous prime&#x02013;boost COVID-19 vaccination<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR107">107</xref>,<xref ref-type="bibr" rid="CR111">111</xref></sup>. The development of ChAdOx1 nCoV-19 is based on promising human studies with ChAdOx1-MERS vaccine<sup><xref ref-type="bibr" rid="CR112">112</xref></sup> and ChAdOx1-TB vaccine<sup><xref ref-type="bibr" rid="CR113">113</xref></sup>. However, although intramuscular delivery of ChAdOx1 nCoV-19 reduced SARS-CoV-2 viral load in the lungs and prevented pneumonia in rhesus macaques, it did not reduce viral loads in the upper respiratory tract<sup><xref ref-type="bibr" rid="CR114">114</xref></sup>. A recently reported phase I/II study shows its safety and the induction of potent neutralizing antibody and T cell responses following a single parenteral injection, which are boosted further by a second homologous vaccination<sup><xref ref-type="bibr" rid="CR115">115</xref></sup>. It remains unclear from this trial to what extent both CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets were activated.</p><p id="Par43">VSV-S is a replication-competent COVID-19 vaccine under development by Merck<sup><xref ref-type="bibr" rid="CR116">116</xref></sup> and other groups. Merck&#x02019;s vaccine is built upon the licensure of its highly efficacious VSV-Ebola vaccine, which induces neutralizing antibodies and cellular immunity against Ebola virus surface glycoprotein<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. VSV is a veterinary virus to which humans have no pre-existing immunity. However, the cloning capacity of the VSV vector is limited to 4&#x02009;kb, and its suitability for respiratory mucosal vaccination is unclear. A single parenteral vaccination with a VSV vector expressing S protein provides protection against SARS-CoV-2 in both mouse and hamster models<sup><xref ref-type="bibr" rid="CR118">118</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup>. Among other viral-vectored candidates is non-replicating MVA. MVA has widely been explored as a vaccine carrier and has a cloning capacity of up to 30&#x02009;kb. However, as it is not robustly immunogenic, MVA is often used as a booster vaccine or repeated injection is required to be effective, as was the case in clinical testing of an MVA-MERS-S vaccine<sup><xref ref-type="bibr" rid="CR120">120</xref></sup>.</p></sec><sec id="Sec18"><title>Inactivated viral vaccines</title><p id="Par44">Physically or chemically inactivated viruses have been used successfully in human vaccines against polio, hepatitis A and influenza<sup><xref ref-type="bibr" rid="CR121">121</xref>,<xref ref-type="bibr" rid="CR122">122</xref></sup>. Inactivated viruses can be rapidly generated and scaled up in a pandemic situation using well-established infrastructure and methods<sup><xref ref-type="bibr" rid="CR123">123</xref></sup>. Inactivated viral vaccines have few safety concerns, unlike their live attenuated counterparts, and they express a wide range of native viral antigens, including surface antigens with retained epitope conformations that can induce conformation-dependent antibody responses<sup><xref ref-type="bibr" rid="CR124">124</xref>,<xref ref-type="bibr" rid="CR125">125</xref></sup>.</p><p id="Par45">Currently, there are five early clinical trials to assess inactivated SARS-CoV-2 vaccines (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), with an additional nine candidates in preclinical development<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. PiCoVacc, an inactivated SARS-CoV-2 and alum-adjuvanted vaccine developed by Sinovac Biotech Ltd in China, is the most advanced candidate with published preclinical results<sup><xref ref-type="bibr" rid="CR126">126</xref></sup>. It protects rhesus macaques against SARS-CoV-2, with reduced viral titres and immunopathology associated with antibodies to S protein and nucleocapsid<sup><xref ref-type="bibr" rid="CR126">126</xref></sup>. BBIBP-CorV, another inactivated virus candidate, which is being developed by Chinese state-owned Sinopharm, was tested in a range of animal models, with demonstrated efficacy in non-human primates<sup><xref ref-type="bibr" rid="CR127">127</xref></sup>. Although these findings provide optimism, the observations were made in rather short-term studies and should be interpreted with caution.</p><p id="Par46">Inactivated viral vaccines often require an adjuvant and repeated administration to be effective (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The use of alum as an adjuvant<sup><xref ref-type="bibr" rid="CR126">126</xref>,<xref ref-type="bibr" rid="CR127">127</xref></sup> makes them unsuitable for respiratory mucosal delivery<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>. Although the protection mediated by intramuscular immunization with PiCoVacc or BBIBP-CorV indicates some level of mucosal immunity, probably through the transport of systemic antibodies to the lungs, the durability of such immunity remains unclear as SARS-CoV-2 challenge was performed 1&#x02013;4 weeks after vaccination<sup><xref ref-type="bibr" rid="CR126">126</xref>,<xref ref-type="bibr" rid="CR127">127</xref></sup>. Furthermore, similarly to protein subunit vaccines, inactivated viral vaccines are poor inducers of cytotoxic CD8<sup>+</sup> T cells, which are likely to be required for an effective COVID-19 vaccine.</p><p id="Par47">Studies with inactivated SARS-CoV and respiratory syncytial virus vaccines have reported vaccine-related enhancement of disease, likely involving a T<sub>H</sub>2 cell response and lung eosinophilia, which may be worsened in aged hosts<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR129">129</xref></sup>. Although PiCoVacc or BBIBP-CorV did not worsen lung disease within 7 days after infection, alum is known to drive T<sub>H</sub>2 cell-mediated immune responses, which warrants further safety investigations. The use of T<sub>H</sub>1 cell-skewing modified alum or other adjuvants such as CpG may avert such safety concerns<sup><xref ref-type="bibr" rid="CR130">130</xref>,<xref ref-type="bibr" rid="CR131">131</xref></sup>.</p></sec><sec id="Sec19"><title>Protein subunit vaccines</title><p id="Par48">Currently, there are seven COVID-19 subunit vaccines in clinical trials (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), with 50 other candidates under preclinical development, making this the most common platform<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Subunit vaccines primarily induce CD4<sup>+</sup> T<sub>H</sub> cell and antibody responses. Therefore, most of these vaccines contain full-length SARS-CoV-2 S protein or portions of it with the goal of inducing neutralizing antibodies, similarly to the majority of SARS and MERS vaccines, which had differing levels of efficacy<sup><xref ref-type="bibr" rid="CR132">132</xref>&#x02013;<xref ref-type="bibr" rid="CR134">134</xref></sup>.</p><p id="Par49">Subunit vaccines can be designed to focus the immune response towards neutralizing epitopes, thereby averting the production of non-neutralizing antibodies that may promote ADE of disease<sup><xref ref-type="bibr" rid="CR135">135</xref></sup>. However, unlike nucleic acid-based or viral-vectored vaccines, recombinant S proteins in subunit vaccines could have an improper epitope conformation unless they are produced in mammalian cells<sup><xref ref-type="bibr" rid="CR136">136</xref></sup>. Proteins or peptides alone are poorly immunogenic and generally require not only an adjuvant but also repeated administration, and they are poor activators of CD8<sup>+</sup> T cell responses (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Furthermore, this platform is generally unsuitable for respiratory mucosal vaccination. As is the case for inactivated viral vaccines, use of unmodified alum as an adjuvant skews the immune response towards T<sub>H</sub>2 cell-like responses<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, which is undesirable for host defence against SARS-CoV-2 and may have a role in ADE of disease<sup><xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR130">130</xref></sup>. In this regard, subunit COVID-19 vaccines being developed by GlaxoSmithKline and Novavax use AS03 and Matrix-M adjuvants, respectively<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p></sec><sec id="Sec20"><title>Virus-like particles</title><p id="Par50">VLPs are spontaneously forming particles composed of several structural viral proteins that are co-expressed or admixed. Several commercial vaccines, such as hepatitis B and human papillomavirus vaccines, are based on VLPs<sup><xref ref-type="bibr" rid="CR137">137</xref></sup>. In the case of enveloped coronaviruses, VLPs form when the viral proteins S, M and E, with or without N, are co-expressed in eukaryotic producer cells<sup><xref ref-type="bibr" rid="CR138">138</xref>,<xref ref-type="bibr" rid="CR139">139</xref></sup>. This results in active budding from the producer cells of VLPs that are structurally identical to the infectious virus but lack the viral genome and thus are non-infectious. The presence of S protein on the surface of VLPs enables them to bind and enter ACE2<sup>+</sup> cells in the same manner as the parent virus<sup><xref ref-type="bibr" rid="CR140">140</xref></sup>. Unlike subunit vaccines, the array of S protein on the VLP surface crosslinks the B cell receptor and directly activates B cells, but, like subunit and inactivated viral vaccines, VLPs also typically require an adjuvant and repeated administration<sup><xref ref-type="bibr" rid="CR137">137</xref></sup>. Notwithstanding this, the VLP technology is well established, the biology and safety of coronavirus VLPs are understood and their large-scale production to Good Manufacturing Practice standards is relatively straightforward.</p><p id="Par51">Currently, there is only 1 VLP-based COVID-19 vaccine in clinical trials (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), with 12 more under preclinical development<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. These are produced either in vivo from a viral vector, such as MVA, that expresses the VLP components (a platform being developed by GeoVax) or more often in vitro from producer cells. Notably, Medicago, a Canadian company, produces its SARS-CoV-2 VLPs from genetically engineered plants. Its unpublished results seem to suggest efficacy in inducing neutralizing antibodies in mice<sup><xref ref-type="bibr" rid="CR141">141</xref></sup>.</p></sec><sec id="Sec21"><title>Nucleic acid-based vaccines</title><p id="Par52">Recombinant plasmid DNA has been explored as a vaccine platform for decades, whereas mRNA has emerged more recently as a promising platform<sup><xref ref-type="bibr" rid="CR142">142</xref>,<xref ref-type="bibr" rid="CR143">143</xref></sup>. Currently, there are 6 mRNA-based COVID-19 vaccines and 4 DNA-based COVID-19 vaccines in clinical trials (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), with 27 such vaccines (16 mRNA-based and 11 DNA-based vaccines) under preclinical development<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par53">The antigen-encoding mRNA complexed with a carrier such as lipid nanoparticles can be efficiently delivered in vivo into the cytoplasm of host cells for protein translation and post-translational modifications<sup><xref ref-type="bibr" rid="CR142">142</xref>,<xref ref-type="bibr" rid="CR144">144</xref></sup>, which is an advantage over recombinant protein subunit vaccines. mRNA vaccines are non-infectious and are synthesized by in vitro transcription, free of microbial molecules. These beneficial features differentiate mRNA vaccines from live attenuated viral vaccines, inactivated viral vaccines, subunit vaccines and recombinant viral-vectored vaccines in terms of safety, efficacy and&#x000a0;issues of antivector immunity, enabling their rapid&#x000a0;and inexpensive production and repeated vaccination<sup><xref ref-type="bibr" rid="CR142">142</xref></sup> (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par54">mRNA-1273, which is produced by Moderna, an American biotech company that has experience with mRNA-based MERS vaccines, encodes a prefusion-stabilized SARS-CoV-2 S protein encapsulated in lipid nanoparticles. It entered clinical testing even before the release of preclinical data<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. Recently published phase I clinical trial data indicate that low and medium doses of two repeated parenteral injections are generally safe and induce strong S protein-specific antibody responses and a primarily CD4<sup>+</sup> T cell response in most trial participants<sup><xref ref-type="bibr" rid="CR146">146</xref></sup>. Pfizer and BioNTech are also assessing an mRNA&#x02013;lipid nanoparticle vaccine encoding the S protein RBD (known as BNT162b1) in humans, who developed robust S protein-specific antibody and CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses following two repeated parenteral injections<sup><xref ref-type="bibr" rid="CR147">147</xref>,<xref ref-type="bibr" rid="CR148">148</xref></sup>. The Pfizer/BioNTech and Moderna vaccines have both been selected for US&#x000a0;Operation Warp Speed<sup><xref ref-type="bibr" rid="CR97">97</xref></sup> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par55">Although no mRNA vaccine has yet been licensed for human use, their potential is supported by previous studies of influenza, rabies and Zika virus infections in animals<sup><xref ref-type="bibr" rid="CR149">149</xref>&#x02013;<xref ref-type="bibr" rid="CR153">153</xref></sup>. For example, an mRNA vaccine for influenza virus induced long-term humoral immunity in young and aged mice<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>, and an mRNA vaccine for Zika virus induced both antibodies and cytotoxic CD8<sup>+</sup> T cells in mice<sup><xref ref-type="bibr" rid="CR154">154</xref></sup>. However, two clinical studies show disparities in the magnitude and longevity of immune responses induced by mRNA vaccines<sup><xref ref-type="bibr" rid="CR152">152</xref>,<xref ref-type="bibr" rid="CR155">155</xref></sup>. Thus, although mRNA-based COVID-19 vaccines show promise from early clinical testing, questions remain about their protective efficacy in humans. It is also unclear whether mRNA vaccines are amenable to respiratory mucosal delivery.</p><p id="Par56">Plasmid DNA vaccines share several characteristics with mRNA vaccines, including safety, ease of production and scalability<sup><xref ref-type="bibr" rid="CR156">156</xref></sup>. However, they are poorly immunogenic, requiring multiple doses and the addition of an adjuvant. Currently, there are four plasmid DNA-based COVID-19 vaccines in clinical testing (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), with 11 more under preclinical development. INO-4800, a plasmid DNA vaccine expressing SARS-CoV-2 S protein, is being developed by the US biotech company Inovio Pharmaceuticals. A preclinical study in mice and guinea pigs examined the immunogenicity of this vaccine but did not provide any data pertaining to protection against challenge<sup><xref ref-type="bibr" rid="CR157">157</xref></sup>. Two repeated injections of an S protein-expressing plasmid DNA vaccine resulted in robust protective immunity in rhesus macaques<sup><xref ref-type="bibr" rid="CR158">158</xref></sup>.</p></sec></sec><sec id="Sec22"><title>Conclusions and outlook</title><p id="Par57">The world is in dire need of safe, effective COVID-19 vaccine strategies. Many laboratories and companies have scrambled to rapidly develop these vaccines, resulting in more than 160 vaccine candidates, with a handful having entered phase I, II and III clinical trials within a short period of 6 months. Although we are just beginning to understand COVID-19 and its vaccine requirements, most of the advanced vaccine platforms have been extensively explored for other infections and cancer<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR95">95</xref>,<xref ref-type="bibr" rid="CR96">96</xref>,<xref ref-type="bibr" rid="CR159">159</xref></sup>. While it is important to pursue various vaccine strategies in parallel, it is equally important not to lose sight of this existing scientific knowledge to make well-informed decisions around which strategies to prioritize.</p><p id="Par58">The various vaccine platforms and strategies have their immunological pros and cons (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), but modern immunological principles and data from prior studies of similar platforms lead us to surmise that a parenteral COVID-19 vaccine strategy capable of inducing a robust, durable response involving both neutralizing antibodies and T cells should provide a significant level of protection. Almost all of the current vaccines in the human immunization programme are delivered via the skin or muscle, and most of the current COVID-19 vaccine strategies also focus on the parenteral route of vaccination (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). We further surmise that a respiratory mucosal vaccine strategy capable of inducing these responses directly in the respiratory mucosa will be most effective in the early control or clearance of SARS-CoV-2. This is particularly relevant to high-risk elderly populations, who will require a particularly robust vaccine strategy. In this regard, a respiratory mucosal vaccine strategy for COVID-19 may draw on the successful experience in respiratory mucosal delivery of influenza, measles and TB vaccines to humans<sup><xref ref-type="bibr" rid="CR160">160</xref>&#x02013;<xref ref-type="bibr" rid="CR162">162</xref></sup>. Respiratory mucosal vaccination also has the advantages of being needle-free and requiring a much smaller dose than the parenteral route. However, compared with the parenteral route, fewer vaccine platforms are safe and effective for respiratory mucosal vaccination. Furthermore, the use of inhalational devices for respiratory mucosal delivery may potentially be a limiting factor for widespread application in resource-poor settings.</p><p id="Par59">According to the pandemic vaccine development paradigm (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), the conventional vaccine development milestones are compressed from a time frame of 10&#x02013;15 years to 1&#x02013;2 years, with overlapping preclinical, clinical and scale-up manufacturing processes occurring in parallel<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Owing to the accelerated development process, the interim data from ongoing clinical and preclinical vaccine studies are being published almost in real time. As a result, crucial information about the longevity and quality of vaccine-induced protective immunity is unavailable. As transmission rates and the numbers of new cases have reduced in many countries, it is uncertain whether the phase II and phase III studies of the front-runner candidates will reach a reliable conclusion with regard to their protective efficacy. Furthermore, these vaccine candidates have been studied in isolation, which makes it difficult to directly compare the effectiveness of different candidates. Thus, it would be premature to hail the safety and immunogenicity observed in COVID-19 vaccine trials as a real success. To a large extent, such outcomes could be anticipated from past studies testing the same platforms and delivery routes. Nevertheless, rapid deployment of a vaccine with preclinical efficacy data but limited clinical data to high-risk populations may be necessary (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Evolving scenarios for global COVID-19 vaccine development and demand.</title><p>In response to the urgent demand for a vaccine, more than two dozen candidate vaccines are advancing through clinical trials following an expedited pandemic vaccine development paradigm, with many steps of the development process occurring in parallel before a successful outcome of previous steps has been confirmed. Vaccine candidates will continue to be preclinically and clinically evaluated following conventional and/or rationalized vaccine development processes over the next few years. These efforts will evolve to meet the demands for vaccination in several likely scenarios that are predicted on the basis of sociopolitical challenges and the emerging data regarding the trajectory of the coronavirus disease 2019 (COVID-19) pandemic and the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One scenario is the priority vaccination of high-risk populations such as health-care workers, seniors, people with co-morbidities and ethnic minorities, who have been disproportionately affected by COVID-19, when vaccine supply is initially limited. Aside from these prioritized groups, it may also be necessary to consider that asymptomatic individuals, patients who have recovered from COVID-19 but generated poor immunity or whose immunity quickly waned, and individuals who received a rapidly developed &#x02018;pandemic&#x02019; vaccine that provided suboptimal protection or rapidly waning immune responses may require a booster vaccination to ensure sufficient levels of population protection for herd immunity. Ultimately, regional, continental and global populations will be subject to mass vaccination programmes based on the extent of national and global vaccine distribution and also likely according to the relative regional severity of outbreaks.</p></caption><graphic xlink:href="41577_2020_434_Fig2_HTML" id="d30e3100"/></fig></p><p id="Par60">The evolving process of vaccine development will continue over the next few years until more clinical trials are completed, additional vaccine strategies are evaluated and host defence against SARS-CoV-2, including postinfection immunity, is better understood (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Probably not until then will global mass immunization become a reality. It is possible that the populations that receive the first round of vaccines will have waning immunity and require boosting using improved second-generation COVID-19 vaccines. Furthermore, in addition to unexposed individuals, some individuals who have recovered from COVID-19 who develop poor or waning immunity may also require vaccination<sup><xref ref-type="bibr" rid="CR163">163</xref></sup>.</p><p id="Par61">Given the challenges in resources, manufacturing and issues associated with distribution and regional protectionism, the implementation of vaccination programmes will likely be uneven, asynchronous and variable &#x02014; involving different vaccine platforms and strategies around the globe<sup><xref ref-type="bibr" rid="CR164">164</xref>,<xref ref-type="bibr" rid="CR165">165</xref></sup>. In this regard, some resource-rich countries have already secured large numbers of doses of different candidate vaccines without knowing which one may prove effective. The heated debate has begun globally over who should be at the front of the line when vaccine supply is limited. The founding of the COVID-19 Vaccines Global Access (COVAX) Facility by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO is an attempt to garner resources and unite higher- and lower-income countries for the coordinated, rapid, transparent and equitable access to COVID-19 vaccines worldwide.</p></sec></body><back><fn-group><fn><p><bold>Peer review information</bold></p><p><italic>Nature Reviews Immunology</italic> thanks P. Klenerman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.</p></fn><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p><bold>Related links</bold></p><p>
<bold>Australian New Zealand Clinical Trials Registry (ANZCTR):</bold>
<ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/">http://www.anzctr.org.au/</ext-link>
</p><p>
<bold>Chinese Clinical Trial Registry (ChiCTR):</bold>
<ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/index.aspx">http://www.chictr.org.cn/index.aspx</ext-link>
</p><p>
<bold>ClinicalTrials.gov:</bold>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>
</p><p><bold>EU Clinical Trials Register (EudraCT)</bold>: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/">https://www.clinicaltrialsregister.eu/</ext-link></p><p>
<bold>ISRCTN registry:</bold>
<ext-link ext-link-type="uri" xlink:href="https://www.isrctn.com/">https://www.isrctn.com/</ext-link>
</p><p>
<bold>Pan African Clinical Trials Registry (PACTR):</bold>
<ext-link ext-link-type="uri" xlink:href="https://pactr.samrc.ac.za/">https://pactr.samrc.ac.za/</ext-link>
</p></fn><fn><p>These authors contributed equally: Mangalakumari Jeyanathan, Sam Afkhami.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The work was supported by the Canadian Institutes of Health Research (CIHR) COVID-19 Rapid Research Program, the CIHR Foundation Program, the National Sanitarium Association of Canada Innovative Research Program, the Natural Sciences and Engineering Research Council of Canada, the Canadian Foundation for Innovation, Ontario Government, and McMaster University.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors contributed equally to all aspects of the article.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par62">The authors declare no competing interests.</p></notes><glossary><title>Glossary</title><def-list><def-item id="Glos1"><term>Acute respiratory distress syndrome</term><def><p>A rapidly developing lung condition characterized by deficient oxygen exchange and shortness of breath, resulting from severe lung injury and inflammation following infection.</p></def></def-item><def-item id="Glos2"><term>Immunosenescence</term><def><p>Age-related changes in the immune system that lead to a progressive reduction in its ability to develop effective antibody and cellular responses to infections and vaccinations.</p></def></def-item><def-item id="Glos3"><term>Trained immunity</term><def><p>A persisting reset state of the innate immune system long after the initial antigen or microbial exposure that leads to enhanced responsiveness to the same or an unrelated antigen or microorganism.</p></def></def-item><def-item id="Glos4"><term>Fc-mediated effector functions</term><def><p>Immune functions that are mediated through the interaction of the constant Fc region of antibodies with innate immune molecules, complement proteins and specialized Fc receptors expressed by innate immune cells. The resulting functions include complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis or cell-mediated cytotoxicity.</p></def></def-item><def-item id="Glos5"><term>Respiratory mucosal vaccination</term><def><p>Direct administration of a vaccine to the respiratory tract by either intranasal delivery or aerosol inhalation.</p></def></def-item><def-item id="Glos6"><term>Parenteral vaccination</term><def><p>Administration of a vaccine via the skin, muscle or blood vessel.</p></def></def-item><def-item id="Glos7"><term>Antibody-dependent enhancement</term><def><p>(ADE). ADE of disease results when vaccine-induced non-neutralizing or weakly neutralizing antibodies bind to newly infecting virus to promote enhanced virus uptake into host cells via Fc&#x003b3; receptors. This phenomenon has been observed experimentally or clinically following vaccination against viral pathogens such as dengue virus, respiratory syncytial virus and feline coronavirus.</p></def></def-item><def-item id="Glos8"><term>Macrophage activation syndrome</term><def><p>Also known as cytokine storm or secondary hemophagocytic lymphohistocytosis. A clinical state of systemic hyperinflammation that is characterized by hypercytokinaemia, fever, adenopathy, hepatosplenomegaly, cytopenias and activation of intravascular coagulation.</p></def></def-item><def-item id="Glos9"><term>Virus-like particles</term><def><p>(VLPs). A type of subunit vaccine based on multiple virus-derived proteins that are assembled to mimic the organization and conformation of authentic native viruses but that lack the viral genome.</p></def></def-item><def-item id="Glos10"><term>Adjuvants</term><def><p>Biochemical components additional to vaccine antigens that are included in a vaccine formulation to help stimulate an adaptive immune response to vaccine antigens by activating innate immune cells. Often, non-live vaccines such as inactivated virus, protein subunit and nucleic acid vaccines require immune adjuvants.</p></def></def-item><def-item id="Glos11"><term>Homologous or heterologous prime&#x02013;boost vaccination</term><def><p>A repeated immunization regimen designed to increase and sustain vaccine-induced immune responses. It may involve repeated delivery of the same vaccine (homologous) or sequential delivery of different vaccine platforms (heterologous).</p></def></def-item><def-item id="Glos12"><term>US Operation Warp Speed</term><def><p>A public&#x02013;private partnership initiated and funded by the US government to accelerate and coordinate the development, manufacture and distribution of coronavirus disease 2019 (COVID-19) vaccines, therapeutics and diagnostics. It was introduced by the Trump administration in early April 2020.</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. WHO coronavirus disease (COVID-19) dashboard. <italic>WHO</italic><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/">https://covid19.who.int/</ext-link> (2020).</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>R</given-names></name><etal/></person-group><article-title>Epidemiology of and risk factors for coronavirus infection in health care workers</article-title><source>Ann. Intern. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.7326/M20-1632</pub-id><?supplied-pmid 32853032?><pub-id pub-id-type="pmid">32853032</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flaxman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe</article-title><source>Nature</source><year>2020</year><volume>584</volume><fpage>257</fpage><lpage>261</lpage><?supplied-pmid 32512579?><pub-id pub-id-type="pmid">32512579</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanche</surname><given-names>S</given-names></name><etal/></person-group><article-title>High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>1470</fpage><lpage>1477</lpage><?supplied-pmid 32255761?><pub-id pub-id-type="pmid">32255761</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">World Health Organization. Draft landscape of COVID-19 candidate vaccines. <italic>WHO</italic><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link> (2020).</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurie</surname><given-names>N</given-names></name><name><surname>Saville</surname><given-names>M</given-names></name><name><surname>Hatchett</surname><given-names>R</given-names></name><name><surname>Halton</surname><given-names>J</given-names></name></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1969</fpage><lpage>1973</lpage><?supplied-pmid 32227757?><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Chau, N. V. V. et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. <italic>Clin. Infect. Dis</italic>. 10.1093/cid/ciaa711 (2020).</mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Poletti, P. et al. Probability of symptoms and critical disease after SARS-CoV-2 infection. Preprint at <italic>arXiv</italic><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2006.08471">https://arxiv.org/abs/2006.08471</ext-link> (2020). <bold>Chau et al. (2020) and Poletti et al. indicate high rates of asymptomatic individuals following SARS-CoV-2 exposure</bold>.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>Q-X</given-names></name><etal/></person-group><article-title>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1200</fpage><lpage>1204</lpage><?supplied-pmid 32555424?><pub-id pub-id-type="pmid">32555424</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sungnak</surname><given-names>W</given-names></name><etal/></person-group><article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>681</fpage><lpage>687</lpage><?supplied-pmid 32327758?><pub-id pub-id-type="pmid">32327758</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>X</given-names></name><etal/></person-group><article-title>Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection</article-title><source>Front. Med.</source><year>2020</year><volume>14</volume><fpage>185</fpage><lpage>192</lpage><?supplied-pmid 32170560?><pub-id pub-id-type="pmid">32170560</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280.e8</lpage><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallenave</surname><given-names>J-M</given-names></name><name><surname>Guillot</surname><given-names>L</given-names></name></person-group><article-title>Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets?</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>1229</fpage><?supplied-pmid 32574272?><pub-id pub-id-type="pmid">32574272</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puelles</surname><given-names>VG</given-names></name><etal/></person-group><article-title>Multiorgan and renal tropism of SARS-CoV-2</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>590</fpage><lpage>592</lpage><?supplied-pmid 32402155?><pub-id pub-id-type="pmid">32402155</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>523</fpage><lpage>534</lpage><?supplied-pmid 27344959?><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prompetchara</surname><given-names>E</given-names></name><name><surname>Ketloy</surname><given-names>C</given-names></name><name><surname>Palaga</surname><given-names>T</given-names></name></person-group><article-title>Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic</article-title><source>Asian Pac. J. Allergy Immunol.</source><year>2020</year><volume>38</volume><fpage>1</fpage><lpage>9</lpage><?supplied-pmid 32105090?><pub-id pub-id-type="pmid">32105090</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Sariol, A. &#x00026; Perlman, S. Lessons for COVID-19 immunity from other coronavirus infections. <italic>Immunity</italic>10.1016/j.immuni.2020.07.005 (2020).</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R</given-names></name><etal/></person-group><article-title>Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses</article-title><source>Immunity</source><year>2020</year><volume>53</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">32610080</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remy</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Severe immunosuppression and not a cytokine storm characterize COVID-19 infections</article-title><source>JCI Insight</source><year>2020</year><pub-id pub-id-type="doi">10.1172/jci.insight.140329</pub-id><?supplied-pmid 32687484?><pub-id pub-id-type="pmid">32687484</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Melo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Imbalanced host response to SARS-CoV-2 drives development of COVID-19</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1036</fpage><lpage>1045.e9</lpage><?supplied-pmid 32416070?><pub-id pub-id-type="pmid">32416070</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>JC</given-names></name></person-group><article-title>Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>355</fpage><lpage>362</lpage><?supplied-pmid 32376901?><pub-id pub-id-type="pmid">32376901</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients</article-title><source>Natl Sci. Rev.</source><year>2020</year><volume>7</volume><fpage>998</fpage><lpage>1002</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1054</fpage><lpage>1062</lpage><?supplied-pmid 32171076?><pub-id pub-id-type="pmid">32171076</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>842</fpage><lpage>844</lpage><?supplied-pmid 32398875?><pub-id pub-id-type="pmid">32398875</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulop</surname><given-names>T</given-names></name><etal/></person-group><article-title>Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes?</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1960</fpage><?supplied-pmid 29375577?><pub-id pub-id-type="pmid">29375577</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haq</surname><given-names>K</given-names></name><name><surname>McElhaney</surname><given-names>JE</given-names></name></person-group><article-title>Immunosenescence: influenza vaccination and the elderly</article-title><source>Curr. Opin. Immunol.</source><year>2014</year><volume>29</volume><fpage>38</fpage><lpage>42</lpage><?supplied-pmid 24769424?><pub-id pub-id-type="pmid">24769424</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>MZ</given-names></name><name><surname>Poh</surname><given-names>CM</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L</given-names></name><name><surname>MacAry</surname><given-names>PA</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name></person-group><article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>363</fpage><lpage>374</lpage><?supplied-pmid 32346093?><pub-id pub-id-type="pmid">32346093</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa344</pub-id><?supplied-pmid 32750119?><pub-id pub-id-type="pmid">32750119</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>L</given-names></name><etal/></person-group><article-title>Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>971</fpage><lpage>977.e3</lpage><?supplied-pmid 32413330?><pub-id pub-id-type="pmid">32413330</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grifoni</surname><given-names>A</given-names></name><etal/></person-group><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>1489</fpage><lpage>1501.e15</lpage><?supplied-pmid 32473127?><pub-id pub-id-type="pmid">32473127</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1582</fpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seow</surname><given-names>J</given-names></name><etal/></person-group><article-title>Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.09.20148429</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>281</fpage><lpage>292.e6</lpage><?supplied-pmid 32155444?><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>290</fpage><lpage>295</lpage><?supplied-pmid 32422645?><pub-id pub-id-type="pmid">32422645</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Hillyer</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</article-title><source>Trends Immunol.</source><year>2020</year><volume>41</volume><fpage>355</fpage><lpage>359</lpage><?supplied-pmid 7129017?><pub-id pub-id-type="pmid">32249063</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>J</given-names></name><etal/></person-group><article-title>A human SARS-CoV neutralizing antibody against epitope on S2 protein</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2005</year><volume>333</volume><fpage>186</fpage><lpage>193</lpage><?supplied-pmid 15939399?><pub-id pub-id-type="pmid">15939399</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughlin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse&#x000ae;</article-title><source>Virology</source><year>2007</year><volume>361</volume><fpage>93</fpage><lpage>102</lpage><?supplied-pmid 17161858?><pub-id pub-id-type="pmid">17161858</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KKW</given-names></name><etal/></person-group><article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>565</fpage><lpage>574</lpage><?supplied-pmid 32213337?><pub-id pub-id-type="pmid">32213337</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2</article-title><source>J. Clin. Microbiol.</source><year>2020</year><volume>58</volume><fpage>e00461-20</fpage><?supplied-pmid 32229605?><pub-id pub-id-type="pmid">32229605</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>QX</given-names></name><etal/></person-group><article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>845</fpage><lpage>848</lpage><?supplied-pmid 32350462?><pub-id pub-id-type="pmid">32350462</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakanaga</surname><given-names>K</given-names></name><name><surname>Yamanouchi</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name></person-group><article-title>Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice</article-title><source>J. Virol.</source><year>1986</year><volume>59</volume><fpage>168</fpage><lpage>171</lpage><?supplied-pmid 3012115?><pub-id pub-id-type="pmid">3012115</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecomte</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody</article-title><source>Arch. Virol.</source><year>1987</year><volume>97</volume><fpage>123</fpage><lpage>130</lpage><?supplied-pmid 2825619?><pub-id pub-id-type="pmid">2825619</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients</article-title><source>Eur. Respir. J.</source><year>2020</year><pub-id pub-id-type="doi">10.1183/13993003.01526-2020</pub-id><?supplied-pmid 32675204?><pub-id pub-id-type="pmid">32675204</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padoan</surname><given-names>A</given-names></name><etal/></person-group><article-title>IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study</article-title><source>Clin. Chim. Acta</source><year>2020</year><volume>507</volume><fpage>164</fpage><lpage>166</lpage><?supplied-pmid 32343948?><pub-id pub-id-type="pmid">32343948</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W-C</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>P-H</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Richardus</surname><given-names>JH</given-names></name></person-group><article-title>Disappearance of antibodies to SARS-associated coronavirus after recovery</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>357</volume><fpage>1162</fpage><lpage>1163</lpage><?supplied-pmid 17855683?><pub-id pub-id-type="pmid">17855683</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>LP</given-names></name><etal/></person-group><article-title>Duration of antibody responses after severe acute respiratory syndrome</article-title><source>Emerg. Infect. Dis.</source><year>2007</year><volume>13</volume><fpage>1562</fpage><lpage>1564</lpage><?supplied-pmid 18258008?><pub-id pub-id-type="pmid">18258008</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callow</surname><given-names>KA</given-names></name><name><surname>Parry</surname><given-names>HF</given-names></name><name><surname>Sergeant</surname><given-names>M</given-names></name><name><surname>Tyrrell</surname><given-names>DAJ</given-names></name></person-group><article-title>The time course of the immune response to experimental coronavirus infection of man</article-title><source>Epidemiol. Infect.</source><year>1990</year><volume>105</volume><fpage>435</fpage><lpage>446</lpage><?supplied-pmid 2170159?><pub-id pub-id-type="pmid">2170159</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Kolls</surname><given-names>JK</given-names></name></person-group><article-title>T cell&#x02013;mediated host immune defenses in the lung</article-title><source>Annu. Rev. Immunol.</source><year>2013</year><volume>31</volume><fpage>605</fpage><lpage>633</lpage><?supplied-pmid 23516986?><pub-id pub-id-type="pmid">23516986</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arunachalam</surname><given-names>PS</given-names></name><etal/></person-group><article-title>T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>932</fpage><lpage>940</lpage><?supplied-pmid 32393800?><pub-id pub-id-type="pmid">32393800</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group><article-title>T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>9318</fpage><lpage>9325</lpage><?supplied-pmid 20610717?><pub-id pub-id-type="pmid">20610717</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Lung niches for the generation and maintenance of tissue-resident memory T cells</article-title><source>Mucosal Immunol.</source><year>2014</year><volume>7</volume><fpage>501</fpage><lpage>510</lpage><?supplied-pmid 24064670?><pub-id pub-id-type="pmid">24064670</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Smaill</surname><given-names>F</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><article-title>New tuberculosis vaccine strategies: taking aim at un-natural immunity</article-title><source>Trends Immunol.</source><year>2018</year><volume>39</volume><fpage>419</fpage><lpage>433</lpage><?supplied-pmid 29429859?><pub-id pub-id-type="pmid">29429859</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddadi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral TB vaccine-primed hosts requires cognate antigens and CD4 T Cells</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2075</fpage><?supplied-pmid 31552032?><pub-id pub-id-type="pmid">31552032</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Airway memory CD4<sup>+</sup> T cells mediate protective immunity against emerging respiratory coronaviruses</article-title><source>Immunity</source><year>2016</year><volume>44</volume><fpage>1379</fpage><lpage>1391</lpage><?supplied-pmid 27287409?><pub-id pub-id-type="pmid">27287409</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janice Oh</surname><given-names>H-L</given-names></name><name><surname>Ken-En Gan</surname><given-names>S</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>Y-J</given-names></name></person-group><article-title>Understanding the T cell immune response in SARS coronavirus infection</article-title><source>Emerg. Microbes Infect.</source><year>2012</year><volume>1</volume><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolles</surname><given-names>M</given-names></name><etal/></person-group><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>12201</fpage><lpage>12215</lpage><?supplied-pmid 21937658?><pub-id pub-id-type="pmid">21937658</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C-T</given-names></name><etal/></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e35421</fpage><?supplied-pmid 22536382?><pub-id pub-id-type="pmid">22536382</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braun</surname><given-names>J</given-names></name><etal/></person-group><article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2598-9</pub-id><?supplied-pmid 32726801?><pub-id pub-id-type="pmid">32726801</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>SF</given-names></name><name><surname>Quadeer</surname><given-names>AA</given-names></name><name><surname>McKay</surname><given-names>MR</given-names></name></person-group><article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies</article-title><source>Viruses</source><year>2020</year><volume>12</volume><fpage>254</fpage></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateus</surname><given-names>J</given-names></name><etal/></person-group><article-title>Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi">10.1126/science.abd3871</pub-id><?supplied-pmid 32753554?><pub-id pub-id-type="pmid">32753554</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. <italic>Nature</italic>10.1038/s41586-020-2550-z (2020). <bold>Braun et al. (2020), Mateus et al. (2020) and Le Bert et al. consistently find the presence, in a significant proportion of uninfected individuals, of memory CD4</bold><sup><bold>+</bold></sup><bold>T cells cross-reactive to SARS-CoV-2, likely resulting from previous exposure to common cold coronaviruses as well as animal coronaviruses. These findings offer a potential mechanism underlying differential susceptibility to SARS-CoV-2 infection and suggest that a COVID-19 vaccine may boost such pre-existing cross-reactive memory T cells in some individuals</bold>.</mixed-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Screaton</surname><given-names>G</given-names></name><name><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name><surname>Yacoub</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name></person-group><article-title>New insights into the immunopathology and control of dengue virus infection</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>745</fpage><lpage>759</lpage><?supplied-pmid 26603900?><pub-id pub-id-type="pmid">26603900</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue</article-title><source>Eur. Respir. J.</source><year>2020</year><pub-id pub-id-type="doi">10.1183/13993003.01123-2020</pub-id><?supplied-pmid 32675206?><pub-id pub-id-type="pmid">32675206</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><etal/></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1033</fpage><lpage>1034</lpage><?supplied-pmid 32192578?><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulert</surname><given-names>GS</given-names></name><name><surname>Grom</surname><given-names>AA</given-names></name></person-group><article-title>Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies</article-title><source>Annu. Rev. Med.</source><year>2015</year><volume>66</volume><fpage>145</fpage><lpage>159</lpage><?supplied-pmid 25386930?><pub-id pub-id-type="pmid">25386930</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>497</fpage><lpage>506</lpage><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>S</given-names></name><etal/></person-group><article-title>Symptomatic SARS-CoV-2 infections display specific IgG Fc structures</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.05.15.20103341</pub-id><?supplied-pmid 32511463?><pub-id pub-id-type="pmid">32511463</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><etal/></person-group><article-title>Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome</article-title><source>J. Clin. Virol.</source><year>2006</year><volume>35</volume><fpage>179</fpage><lpage>184</lpage><?supplied-pmid 16112612?><pub-id pub-id-type="pmid">16112612</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title><source>JCI Insight</source><year>2019</year><volume>4</volume><fpage>e123158</fpage></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eroshenko</surname><given-names>N</given-names></name><etal/></person-group><article-title>Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures</article-title><source>Nat. Biotechnol.</source><year>2020</year><volume>38</volume><fpage>789</fpage><lpage>791</lpage><?supplied-pmid 32504046?><pub-id pub-id-type="pmid">32504046</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weingartl</surname><given-names>H</given-names></name><etal/></person-group><article-title>Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>12672</fpage><lpage>12676</lpage><?supplied-pmid 15507655?><pub-id pub-id-type="pmid">15507655</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czub</surname><given-names>M</given-names></name><name><surname>Weingartl</surname><given-names>H</given-names></name><name><surname>Czub</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>2273</fpage><lpage>2279</lpage><?supplied-pmid 15755610?><pub-id pub-id-type="pmid">15755610</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kam</surname><given-names>YW</given-names></name><etal/></person-group><article-title>Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc&#x003b3;RII-dependent entry into B cells in vitro</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>729</fpage><lpage>740</lpage><?supplied-pmid 17049691?><pub-id pub-id-type="pmid">17049691</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Pierson</surname><given-names>TC</given-names></name></person-group><article-title>The challenges of vaccine development against a new virus during a pandemic</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>699</fpage><lpage>703</lpage><?supplied-pmid 32407708?><pub-id pub-id-type="pmid">32407708</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchholz</surname><given-names>UJ</given-names></name><etal/></person-group><article-title>Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity</article-title><source>Proc. Natl Acad. Sci.</source><year>2004</year><volume>101</volume><fpage>9804</fpage><lpage>9809</lpage><?supplied-pmid 15210961?><pub-id pub-id-type="pmid">15210961</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephensen</surname><given-names>CB</given-names></name><name><surname>Casebolt</surname><given-names>DB</given-names></name><name><surname>Gangopadhyay</surname><given-names>NN</given-names></name></person-group><article-title>Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay</article-title><source>Virus Res.</source><year>1999</year><volume>60</volume><fpage>181</fpage><lpage>189</lpage><?supplied-pmid 10392726?><pub-id pub-id-type="pmid">10392726</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Structure of the RNA-dependent RNA polymerase from COVID-19 virus</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>779</fpage><lpage>782</lpage><?supplied-pmid 32277040?><pub-id pub-id-type="pmid">32277040</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>S</given-names></name><name><surname>Jasny</surname><given-names>E</given-names></name><name><surname>Schmidt</surname><given-names>KE</given-names></name><name><surname>Petsch</surname><given-names>B</given-names></name></person-group><article-title>New vaccine technologies to combat outbreak situations</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1963</fpage><?supplied-pmid 30283434?><pub-id pub-id-type="pmid">30283434</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>Z</given-names></name></person-group><article-title>Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens</article-title><source>Mol. Ther. Methods Clin. Dev.</source><year>2016</year><volume>3</volume><fpage>16030</fpage><?supplied-pmid 27162933?><pub-id pub-id-type="pmid">27162933</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Fierros</surname><given-names>L</given-names></name><name><surname>Garc&#x000ed;a-Silva</surname><given-names>I</given-names></name><name><surname>Rosales-Mendoza</surname><given-names>S</given-names></name></person-group><article-title>Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?</article-title><source>Expert. Opin. Biol. Ther.</source><year>2020</year><volume>20</volume><fpage>831</fpage><lpage>836</lpage><?supplied-pmid 32380868?><pub-id pub-id-type="pmid">32380868</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belyakov</surname><given-names>IM</given-names></name><name><surname>Ahlers</surname><given-names>JD</given-names></name></person-group><article-title>What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>6883</fpage><lpage>6892</lpage><?supplied-pmid 19923474?><pub-id pub-id-type="pmid">19923474</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>PA</given-names></name><name><surname>Miron</surname><given-names>M</given-names></name><name><surname>Farber</surname><given-names>DL</given-names></name></person-group><article-title>Location, location, location: tissue resident memory T cells in mice and humans</article-title><source>Sci. Immunol.</source><year>2019</year><volume>4</volume><fpage>eaas9673</fpage><?supplied-pmid 30952804?><pub-id pub-id-type="pmid">30952804</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Innate immune memory of tissue-resident macrophages and trained innate immunity: re-vamping vaccine concept and strategies</article-title><source>J. Leukoc. Biol.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/JLB.4MR0220-446R</pub-id><?supplied-pmid 32125045?><pub-id pub-id-type="pmid">32125045</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>969</fpage><lpage>977</lpage><?supplied-pmid 32437659?><pub-id pub-id-type="pmid">32437659</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity</article-title><source>Cell</source><year>2018</year><volume>175</volume><fpage>1634</fpage><lpage>1650.e17</lpage><?supplied-pmid 30433869?><pub-id pub-id-type="pmid">30433869</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plotkin</surname><given-names>S</given-names></name></person-group><article-title>History of vaccination</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>12283</fpage><lpage>12287</lpage><?supplied-pmid 25136134?><pub-id pub-id-type="pmid">25136134</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almaz&#x000e1;n</surname><given-names>F</given-names></name><etal/></person-group><article-title>Engineering a replication-competent, propagation-defective middle east respiratory syndrome coronavirus as a vaccine candidate</article-title><source>MBio</source><year>2013</year><volume>4</volume><fpage>e00650-13</fpage><?supplied-pmid 24023385?><pub-id pub-id-type="pmid">24023385</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netland</surname><given-names>J</given-names></name><etal/></person-group><article-title>Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease</article-title><source>Virology</source><year>2010</year><volume>399</volume><fpage>120</fpage><lpage>128</lpage><?supplied-pmid 20110095?><pub-id pub-id-type="pmid">20110095</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Meulia</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Saif</surname><given-names>LJ</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Deletion of both the tyrosine-based endocytosis signal and the endoplasmic reticulum retrieval signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs</article-title><source>J. Virol.</source><year>2018</year><volume>93</volume><fpage>e01758-18</fpage></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Guarde&#x000f1;o</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><fpage>e1005215</fpage><?supplied-pmid 26513244?><pub-id pub-id-type="pmid">26513244</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>VD</given-names></name><etal/></person-group><article-title>Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2&#x02019;-O-methyltransferase activity</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>4251</fpage><lpage>4264</lpage><?supplied-pmid 24478444?><pub-id pub-id-type="pmid">24478444</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>BYH</given-names></name><name><surname>Ortiz-Ria&#x000f1;o</surname><given-names>E</given-names></name><name><surname>Nogales</surname><given-names>A</given-names></name><name><surname>de la Torre</surname><given-names>JC</given-names></name><name><surname>Mart&#x000ed;nez-Sobrido</surname><given-names>L</given-names></name></person-group><article-title>Development of live-attenuated arenavirus vaccines based on codon deoptimization</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>3523</fpage><lpage>3533</lpage><?supplied-pmid 25589652?><pub-id pub-id-type="pmid">25589652</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>S</given-names></name><etal/></person-group><article-title>A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>2943</fpage><lpage>2948</lpage><?supplied-pmid 32107060?><pub-id pub-id-type="pmid">32107060</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e01953-16</fpage><?supplied-pmid 28077633?><pub-id pub-id-type="pmid">28077633</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphreys</surname><given-names>IR</given-names></name><name><surname>Sebastian</surname><given-names>S</given-names></name></person-group><article-title>Novel viral vectors in infectious diseases</article-title><source>Immunology</source><year>2018</year><volume>153</volume><fpage>1</fpage><lpage>9</lpage><?supplied-pmid 28869761?><pub-id pub-id-type="pmid">28869761</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>SJ</given-names></name><name><surname>Heeney</surname><given-names>JL</given-names></name></person-group><article-title>Viruses as vaccine vectors for infectious diseases and cancer</article-title><source>Nat. Rev. Microbiol.</source><year>2010</year><volume>8</volume><fpage>62</fpage><lpage>73</lpage><?supplied-pmid 19966816?><pub-id pub-id-type="pmid">19966816</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>Top U.S. scientists left out of White House selection of COVID-19 vaccine short list</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi">10.1126/science.abd1719</pub-id><?supplied-pmid 32855320?><pub-id pub-id-type="pmid">32855320</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F-C</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1845</fpage><lpage>1854</lpage><?supplied-pmid 32450106?><pub-id pub-id-type="pmid">32450106</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F-C</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31605-6</pub-id><?supplied-pmid 32758466?><pub-id pub-id-type="pmid">32758466</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smaill</surname><given-names>F</given-names></name><etal/></person-group><article-title>A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity</article-title><source>Sci. Transl Med.</source><year>2013</year><volume>5</volume><fpage>205ra134</fpage><?supplied-pmid 24089406?><pub-id pub-id-type="pmid">24089406</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledgerwood</surname><given-names>JE</given-names></name><etal/></person-group><article-title>A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults</article-title><source>Vaccine</source><year>2010</year><volume>29</volume><fpage>304</fpage><lpage>313</lpage><?supplied-pmid 21034824?><pub-id pub-id-type="pmid">21034824</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study</article-title><source>Lancet. Infect. Dis.</source><year>2011</year><volume>11</volume><fpage>507</fpage><lpage>515</lpage><?supplied-pmid 21570355?><pub-id pub-id-type="pmid">21570355</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa</article-title><source>Emerg. Infect. Dis.</source><year>2006</year><volume>12</volume><fpage>1596</fpage><lpage>1599</lpage><?supplied-pmid 17176582?><pub-id pub-id-type="pmid">17176582</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F-C</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>621</fpage><lpage>628</lpage><?supplied-pmid 28017399?><pub-id pub-id-type="pmid">28017399</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">Cross, R. CanSino publishes first COVID-19 vaccine data to muted response. <italic>Chemical &#x00026; Engineering News</italic><ext-link ext-link-type="uri" xlink:href="https://cen.acs.org/pharmaceuticals/vaccines/CanSino-publishes-first-COVID-19/98/i21">https://cen.acs.org/pharmaceuticals/vaccines/CanSino-publishes-first-COVID-19/98/i21</ext-link> (2020).</mixed-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults</article-title><source>J. Med. Virol.</source><year>2013</year><volume>85</volume><fpage>1077</fpage><lpage>1084</lpage><?supplied-pmid 23588735?><pub-id pub-id-type="pmid">23588735</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colloca</surname><given-names>S</given-names></name><etal/></person-group><article-title>Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species</article-title><source>Sci. Transl Med.</source><year>2012</year><volume>4</volume><fpage>115ra2</fpage><?supplied-pmid 22218691?><pub-id pub-id-type="pmid">22218691</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baden</surname><given-names>LR</given-names></name><etal/></person-group><article-title>First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>207</volume><fpage>240</fpage><lpage>247</lpage><?supplied-pmid 23125444?><pub-id pub-id-type="pmid">23125444</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anywaine</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>220</volume><fpage>46</fpage><lpage>56</lpage><?supplied-pmid 30796818?><pub-id pub-id-type="pmid">30796818</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercado</surname><given-names>NB</given-names></name><etal/></person-group><article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2607-z</pub-id><?supplied-pmid 32788733?><pub-id pub-id-type="pmid">32788733</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewer</surname><given-names>K</given-names></name><etal/></person-group><article-title>Chimpanzee adenoviral vectors as vaccines for outbreak pathogens</article-title><source>Hum. Vaccin. Immunother.</source><year>2017</year><volume>13</volume><fpage>3020</fpage><lpage>3032</lpage><?supplied-pmid 29083948?><pub-id pub-id-type="pmid">29083948</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folegatti</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial</article-title><source>Lancet. Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>816</fpage><lpage>826</lpage><?supplied-pmid 32325038?><pub-id pub-id-type="pmid">32325038</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname><given-names>M</given-names></name><etal/></person-group><article-title>A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime &#x02013; MVA85A boost in healthy UK adults</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>779</fpage><lpage>789</lpage><?supplied-pmid 31735500?><pub-id pub-id-type="pmid">31735500</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N</given-names></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2608-y</pub-id><?supplied-pmid 32731258?><pub-id pub-id-type="pmid">32731258</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folegatti</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31604-4</pub-id><?supplied-pmid 32702298?><pub-id pub-id-type="pmid">32702298</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henao-Restrepo</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>857</fpage><lpage>866</lpage><?supplied-pmid 26248676?><pub-id pub-id-type="pmid">26248676</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><mixed-citation publication-type="other">Cohen, J. Merck, one of Big Pharma&#x02019;s biggest players, reveals its COVID-19 vaccine and therapy plans. <italic>Science</italic>10.1126/science.abd0121 (2020).</mixed-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Case</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice</article-title><source>Cell Host Microbe</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.chom.2020.07.018</pub-id><?supplied-pmid 32798445?><pub-id pub-id-type="pmid">32798445</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yahalom-Ronen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A single dose of recombinant VSV-&#x00394;G-spike vaccine provides protection against SARS-CoV-2 challenge</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.18.160655</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>T</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>827</fpage><lpage>838</lpage><?supplied-pmid 32325037?><pub-id pub-id-type="pmid">32325037</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdin</surname><given-names>AD</given-names></name><name><surname>Barreto</surname><given-names>L</given-names></name><name><surname>Plotkin</surname><given-names>S</given-names></name></person-group><article-title>Inactivated poliovirus vaccine: past and present experience</article-title><source>Vaccine</source><year>1996</year><volume>14</volume><fpage>735</fpage><lpage>746</lpage><?supplied-pmid 8817819?><pub-id pub-id-type="pmid">8817819</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vellozzi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>2114</fpage><lpage>2120</lpage><?supplied-pmid 19356614?><pub-id pub-id-type="pmid">19356614</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>JM</given-names></name><name><surname>Robertson</surname><given-names>JS</given-names></name></person-group><article-title>From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza</article-title><source>Nat. Rev. Microbiol.</source><year>2004</year><volume>2</volume><fpage>842</fpage><lpage>847</lpage><?supplied-pmid 15378048?><pub-id pub-id-type="pmid">15378048</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahir Ul Qamar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epitope-based peptide vaccine design and target site depiction against Middle East respiratory syndrome coronavirus: an immune-informatics study</article-title><source>J. Transl Med.</source><year>2019</year><volume>17</volume><fpage>362</fpage><?supplied-pmid 31703698?><pub-id pub-id-type="pmid">31703698</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Allen</surname><given-names>JD</given-names></name><name><surname>Wrapp</surname><given-names>D</given-names></name><name><surname>McLellan</surname><given-names>JS</given-names></name><name><surname>Crispin</surname><given-names>M</given-names></name></person-group><article-title>Site-specific glycan analysis of the SARS-CoV-2 spike</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>330</fpage><lpage>333</lpage><?supplied-pmid 32366695?><pub-id pub-id-type="pmid">32366695</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>713</fpage><lpage>721.e9</lpage><?supplied-pmid 32778225?><pub-id pub-id-type="pmid">32778225</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>77</fpage><lpage>81</lpage><?supplied-pmid 32376603?><pub-id pub-id-type="pmid">32376603</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>L</given-names></name></person-group><article-title>Mucosal adjuvants: opportunities and challenges</article-title><source>Hum. Vaccin. Immunother.</source><year>2016</year><volume>12</volume><fpage>2456</fpage><lpage>2458</lpage><?supplied-pmid 27159278?><pub-id pub-id-type="pmid">27159278</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Effects of toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>8597</fpage><lpage>8614</lpage><?supplied-pmid 24850731?><pub-id pub-id-type="pmid">24850731</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Giudice</surname><given-names>G</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Didierlaurent</surname><given-names>AM</given-names></name></person-group><article-title>Correlates of adjuvanticity: a review on adjuvants in licensed vaccines</article-title><source>Semin. Immunol.</source><year>2018</year><volume>39</volume><fpage>14</fpage><lpage>21</lpage><?supplied-pmid 29801750?><pub-id pub-id-type="pmid">29801750</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>HogenEsch</surname><given-names>H</given-names></name><name><surname>O&#x02019;Hagan</surname><given-names>DT</given-names></name><name><surname>Fox</surname><given-names>CB</given-names></name></person-group><article-title>Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want</article-title><source>NPJ Vaccines</source><year>2018</year><volume>3</volume><fpage>51</fpage><?supplied-pmid 30323958?><pub-id pub-id-type="pmid">30323958</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mou</surname><given-names>H</given-names></name><etal/></person-group><article-title>The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>9379</fpage><lpage>9383</lpage><?supplied-pmid 23785207?><pub-id pub-id-type="pmid">23785207</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus</article-title><source>DNA Cell Biol.</source><year>2005</year><volume>24</volume><fpage>510</fpage><lpage>515</lpage><?supplied-pmid 16101349?><pub-id pub-id-type="pmid">16101349</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group><article-title>Prospects for a MERS-CoV spike vaccine</article-title><source>Expert. Rev. Vaccines</source><year>2018</year><volume>17</volume><fpage>677</fpage><lpage>686</lpage><?supplied-pmid 30058403?><pub-id pub-id-type="pmid">30058403</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oscherwitz</surname><given-names>J</given-names></name></person-group><article-title>The promise and challenge of epitope-focused vaccines</article-title><source>Hum. Vaccin. Immunother.</source><year>2016</year><volume>12</volume><fpage>2113</fpage><lpage>2116</lpage><?supplied-pmid 27058686?><pub-id pub-id-type="pmid">27058686</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><etal/></person-group><article-title>Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity</article-title><source>Virology</source><year>2009</year><volume>393</volume><fpage>144</fpage><lpage>150</lpage><?supplied-pmid 19683779?><pub-id pub-id-type="pmid">19683779</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donaldson</surname><given-names>B</given-names></name><name><surname>Lateef</surname><given-names>Z</given-names></name><name><surname>Walker</surname><given-names>GF</given-names></name><name><surname>Young</surname><given-names>SL</given-names></name><name><surname>Ward</surname><given-names>VK</given-names></name></person-group><article-title>Virus-like particle vaccines: immunology and formulation for clinical translation</article-title><source>Expert. Rev. Vaccines</source><year>2018</year><volume>17</volume><fpage>833</fpage><lpage>849</lpage><?supplied-pmid 30173619?><pub-id pub-id-type="pmid">30173619</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice</article-title><source>Immunology</source><year>2007</year><volume>122</volume><fpage>496</fpage><lpage>502</lpage><?supplied-pmid 17680799?><pub-id pub-id-type="pmid">17680799</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lokugamage</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>797</fpage><lpage>808</lpage><?supplied-pmid 18191004?><pub-id pub-id-type="pmid">18191004</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naskalska</surname><given-names>A</given-names></name><etal/></person-group><article-title>Novel coronavirus-like particles targeting cells lining the respiratory tract</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>e0203489</fpage><?supplied-pmid 30183777?><pub-id pub-id-type="pmid">30183777</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><mixed-citation publication-type="other">Business Wire. Medicago announces positive results in animal trials for its vaccine candidate against COVID-19. <italic>STT</italic><ext-link ext-link-type="uri" xlink:href="https://www.sttinfo.fi/tiedote/medicago-announces-positive-results-in-animal-trials-for-its-vaccine-candidate-against-covid-19?publisherId=58763726&#x00026;releaseId=69881188">https://www.sttinfo.fi/tiedote/medicago-announces-positive-results-in-animal-trials-for-its-vaccine-candidate-against-covid-19?publisherId=58763726&#x00026;releaseId=69881188</ext-link> (2020).</mixed-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardi</surname><given-names>N</given-names></name><name><surname>Hogan</surname><given-names>MJ</given-names></name><name><surname>Porter</surname><given-names>FW</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA vaccines - a new era in vaccinology</article-title><source>Nat. Rev. Drug. Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><?supplied-pmid 29326426?><pub-id pub-id-type="pmid">29326426</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>NAC</given-names></name><name><surname>Kester</surname><given-names>KE</given-names></name><name><surname>Casimiro</surname><given-names>D</given-names></name><name><surname>Gurunathan</surname><given-names>S</given-names></name><name><surname>DeRosa</surname><given-names>F</given-names></name></person-group><article-title>The promise of mRNA vaccines: a biotech and industrial perspective</article-title><source>NPJ Vaccines</source><year>2020</year><volume>5</volume><fpage>11</fpage><?supplied-pmid 32047656?><pub-id pub-id-type="pmid">32047656</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>J</given-names></name><etal/></person-group><article-title>Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines</article-title><source>NPJ Vaccines</source><year>2017</year><volume>2</volume><fpage>29</fpage><?supplied-pmid 29263884?><pub-id pub-id-type="pmid">29263884</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>KS</given-names></name><etal/></person-group><article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2622-0</pub-id><?supplied-pmid 32756549?><pub-id pub-id-type="pmid">32756549</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>LA</given-names></name><etal/></person-group><article-title>An mRNA vaccine against SARS-CoV-2 - preliminary report</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2022483</pub-id><?supplied-pmid 32877582?><pub-id pub-id-type="pmid">32877582</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2639-4</pub-id><?supplied-pmid 32785213?><pub-id pub-id-type="pmid">32785213</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahin</surname><given-names>U</given-names></name><etal/></person-group><article-title>Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.07.17.20140533</pub-id><?supplied-pmid 32839784?><pub-id pub-id-type="pmid">32839784</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petsch</surname><given-names>B</given-names></name><etal/></person-group><article-title>Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection</article-title><source>Nat. Biotechnol.</source><year>2012</year><volume>30</volume><fpage>1210</fpage><lpage>1216</lpage><?supplied-pmid 23159882?><pub-id pub-id-type="pmid">23159882</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahal</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E4133</fpage><lpage>E4142</lpage><?supplied-pmid 27382155?><pub-id pub-id-type="pmid">27382155</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnee</surname><given-names>M</given-names></name><etal/></person-group><article-title>An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><fpage>e0004746</fpage><?supplied-pmid 27336830?><pub-id pub-id-type="pmid">27336830</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahl</surname><given-names>K</given-names></name><etal/></person-group><article-title>Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>1316</fpage><lpage>1327</lpage><?supplied-pmid 28457665?><pub-id pub-id-type="pmid">28457665</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination</article-title><source>Nature</source><year>2017</year><volume>543</volume><fpage>248</fpage><lpage>251</lpage><?supplied-pmid 28151488?><pub-id pub-id-type="pmid">28151488</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahal</surname><given-names>JS</given-names></name><etal/></person-group><article-title>An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8&#x02009;+&#x02009;T cell responses in a mouse model</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>252</fpage><?supplied-pmid 28325910?><pub-id pub-id-type="pmid">28325910</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberer</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>1511</fpage><lpage>1520</lpage><?supplied-pmid 28754494?><pub-id pub-id-type="pmid">28754494</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobernik</surname><given-names>D</given-names></name><name><surname>Bros</surname><given-names>M</given-names></name></person-group><article-title>DNA vaccines&#x02014;how far from clinical use?</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><fpage>3605</fpage></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>TRF</given-names></name><etal/></person-group><article-title>Immunogenicity of a DNA vaccine candidate for COVID-19</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2601</fpage><?supplied-pmid 32433465?><pub-id pub-id-type="pmid">32433465</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group><article-title>DNA vaccine protection against SARS-CoV-2 in rhesus macaques</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi">10.1126/science.abc6284</pub-id><?supplied-pmid 32820126?><pub-id pub-id-type="pmid">32820126</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichty</surname><given-names>BD</given-names></name><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Stojdl</surname><given-names>DF</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name></person-group><article-title>Going viral with cancer immunotherapy</article-title><source>Nat. Rev. Cancer</source><year>2014</year><volume>14</volume><fpage>559</fpage><lpage>567</lpage><?supplied-pmid 24990523?><pub-id pub-id-type="pmid">24990523</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohn</surname><given-names>KG-I</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Sjursen</surname><given-names>H</given-names></name><name><surname>Cox</surname><given-names>RJ</given-names></name></person-group><article-title>Immune responses after live attenuated influenza vaccination</article-title><source>Hum. Vaccin. Immunother.</source><year>2018</year><volume>14</volume><fpage>571</fpage><lpage>578</lpage><?supplied-pmid 28933664?><pub-id pub-id-type="pmid">28933664</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>N</given-names></name><etal/></person-group><article-title>A randomized, controlled trial of an aerosolized vaccine against measles</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>1519</fpage><lpage>1529</lpage><?supplied-pmid 25875257?><pub-id pub-id-type="pmid">25875257</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satti</surname><given-names>I</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial</article-title><source>Lancet Infect. Dis.</source><year>2014</year><volume>14</volume><fpage>939</fpage><lpage>946</lpage><?supplied-pmid 25151225?><pub-id pub-id-type="pmid">25151225</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Walker</surname><given-names>LM</given-names></name></person-group><article-title>Rational vaccine design in the time of COVID-19</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>695</fpage><lpage>698</lpage><?supplied-pmid 32407707?><pub-id pub-id-type="pmid">32407707</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><mixed-citation publication-type="other">World Economic Forum. 3 challenges in creating a coronavirus vaccine &#x02013; and how they are being overcome. <italic>World Economic Forum</italic><ext-link ext-link-type="uri" xlink:href="https://www.weforum.org/agenda/2020/05/coronavirus-covid-19-vaccine-industry/">https://www.weforum.org/agenda/2020/05/coronavirus-covid-19-vaccine-industry/</ext-link> (2020). <bold>This commentary identifies the three biggest hurdles to COVID-19 vaccine development and vaccination implementation as developing and selecting the safest and most effective vaccine, acquiring large-scale manufacturing capacities and ensuring transparent and fair vaccine distribution</bold>.</mixed-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollyky</surname><given-names>TJ</given-names></name><name><surname>Gostin</surname><given-names>LO</given-names></name><name><surname>Hamburg</surname><given-names>MA</given-names></name></person-group><article-title>The equitable distribution of COVID-19 therapeutics and vaccines</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>2462</fpage></element-citation></ref><ref id="CR166"><label>166.</label><mixed-citation publication-type="other">Laczk&#x000f3;, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. <italic>Immunity</italic>10.1016/j.immuni.2020.07.019 (2020).</mixed-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3523</fpage><?supplied-pmid 32647131?><pub-id pub-id-type="pmid">32647131</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez-Ram&#x000f3;n</surname><given-names>S</given-names></name><etal/></person-group><article-title>Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2936</fpage><?supplied-pmid 30619296?><pub-id pub-id-type="pmid">30619296</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>375</fpage><lpage>388</lpage><?supplied-pmid 32132681?><pub-id pub-id-type="pmid">32132681</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bree</surname><given-names>LCJ</given-names></name><etal/></person-group><article-title>Non-specific effects of vaccines: current evidence and potential implications</article-title><source>Semin. Immunol.</source><year>2018</year><volume>39</volume><fpage>35</fpage><lpage>43</lpage><?supplied-pmid 30007489?><pub-id pub-id-type="pmid">30007489</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uthayakumar</surname><given-names>D</given-names></name><etal/></person-group><article-title>Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>2869</fpage><?supplied-pmid 30564249?><pub-id pub-id-type="pmid">30564249</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>E</given-names></name><etal/></person-group><article-title>BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>176</fpage><lpage>190.e19</lpage><?supplied-pmid 29328912?><pub-id pub-id-type="pmid">29328912</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cirovic</surname><given-names>B</given-names></name><etal/></person-group><article-title>BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment</article-title><source>Cell Host Microbe</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.chom.2020.05.014</pub-id><?supplied-pmid 32544459?><pub-id pub-id-type="pmid">32544459</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJW</given-names></name><etal/></person-group><article-title>BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity</article-title><source>Cell Host Microbe</source><year>2018</year><volume>23</volume><fpage>89</fpage><lpage>100.e5</lpage><?supplied-pmid 29324233?><pub-id pub-id-type="pmid">29324233</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verrall</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Early clearance of mycobacterium tuberculosis is associated with increased innate immune responses</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>221</volume><fpage>1342</fpage><lpage>1350</lpage></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorlag</surname><given-names>SJCFM</given-names></name><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><article-title>Non-specific effects of BCG vaccine on viral infections</article-title><source>Clin. Microbiol. Infect.</source><year>2019</year><volume>25</volume><fpage>1473</fpage><lpage>1478</lpage><?supplied-pmid 31055165?><pub-id pub-id-type="pmid">31055165</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covi&#x000e1;n</surname><given-names>C</given-names></name><name><surname>Retamal-D&#x000ed;az</surname><given-names>A</given-names></name><name><surname>Bueno</surname><given-names>SM</given-names></name><name><surname>Kalergis</surname><given-names>AM</given-names></name><name><surname>Could</surname><given-names>BCG</given-names></name></person-group><article-title>Vaccination induce protective trained immunity for SARS-CoV-2?</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>970</fpage><?supplied-pmid 32574258?><pub-id pub-id-type="pmid">32574258</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>LAJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name></person-group><article-title>BCG-induced trained immunity: can it offer protection against COVID-19?</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>335</fpage><lpage>337</lpage><?supplied-pmid 32393823?><pub-id pub-id-type="pmid">32393823</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordovas-Montanes</surname><given-names>J</given-names></name><name><surname>Beyaz</surname><given-names>S</given-names></name><name><surname>Rakoff-Nahoum</surname><given-names>S</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name></person-group><article-title>Distribution and storage of inflammatory memory in barrier tissues</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>308</fpage><lpage>320</lpage><?supplied-pmid 32015472?><pub-id pub-id-type="pmid">32015472</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardani</surname><given-names>A</given-names></name><name><surname>Boulton</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Braciale</surname><given-names>TJ</given-names></name></person-group><article-title>Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of type-1 alveolar epithelial cells</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><fpage>e1006140</fpage><?supplied-pmid 28085958?><pub-id pub-id-type="pmid">28085958</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillon</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pneumonia recovery reprograms the alveolar macrophage pool</article-title><source>JCI Insight</source><year>2020</year><volume>5</volume><fpage>e133042</fpage></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakdawala</surname><given-names>SS</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name></person-group><article-title>The search for a COVID-19 animal model</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>942</fpage><lpage>943</lpage><?supplied-pmid 32467379?><pub-id pub-id-type="pmid">32467379</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>R</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title><source>J. Virol.</source><year>2020</year><volume>94</volume><fpage>e00127-20</fpage><?supplied-pmid 31996437?><pub-id pub-id-type="pmid">31996437</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockx</surname><given-names>B</given-names></name><etal/></person-group><article-title>Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>1012</fpage><lpage>1015</lpage><?supplied-pmid 32303590?><pub-id pub-id-type="pmid">32303590</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munster</surname><given-names>VJ</given-names></name><etal/></person-group><article-title>Respiratory disease in rhesus macaques inoculated with SARS-CoV-2</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2324-7</pub-id><?supplied-pmid 32731258?><pub-id pub-id-type="pmid">32731258</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS&#x02013;coronavirus 2</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>1016</fpage><lpage>1020</lpage><?supplied-pmid 32269068?><pub-id pub-id-type="pmid">32269068</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Broad and differential animal ACE2 receptor usage by SARS-CoV-2</article-title><source>J. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1128/JVI.00940-20</pub-id><?supplied-pmid 32847852?><pub-id pub-id-type="pmid">32847852</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L</given-names></name><etal/></person-group><article-title>The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice</article-title><source>Nature</source><year>2020</year><volume>583</volume><fpage>830</fpage><lpage>833</lpage><?supplied-pmid 32380511?><pub-id pub-id-type="pmid">32380511</pub-id></element-citation></ref></ref-list></back></article>